



References for the **Geri-RxFiles**

2nd
Edition

ASSESSING MEDICATIONS IN OLDER ADULTS

Alternatives to explore, when less may be more



STOPP

O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing*. 2015 Mar;44(2):213-8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16. PubMed PMID: 25324330; PubMed Central PMCID: PMC4339726.

Available: <http://ageing.oxfordjournals.org/content/44/2/213.long>
<http://ageing.oxfordjournals.org/content/44/2/213/suppl/DC1>

BEERS

By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2015 Oct 8. doi: 10.1111/jgs.13702. [Epub ahead of print] PubMed PMID: 26446832.

Available: <http://geriatricsonline.org/ProductAbstract/american-geriatrics-society-updated-beers-criteria-for-potentially-inappropriate-medication-use-in-older-adults/CL001>

Hanlon JT, Semla TP, Schmader KE. Alternative Medications for Medications in the Use of High-Risk Medications in the Elderly and Potentially Harmful Drug-Disease Interactions in the Elderly Quality Measures. *J Am Geriatr Soc*. 2015 Oct 8. doi: 10.1111/jgs.13807. [Epub ahead of print] PubMed PMID: 26447889.

INTRODUCTION

Drug Therapy in the Older Adult

1. By the American Geriatrics Society 2015 **Beers** Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015 Oct 8. doi: 10.1111/jgs.13702. [Epub ahead of print] PubMed PMID: 26446832.
2. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. **STOPP/START** criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015 Mar;44(2):213-8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16. PubMed PMID: 25324330; PubMed Central PMCID: PMC4339726.
3. Holmes HM. Rational prescribing for patients with a reduced life expectancy. Clin Pharmacol Ther. 2009 Jan;85(1):103-7. doi: 10.1038/clpt.2008.211. Epub 2008 Nov 26. Review. PubMed PMID: 19037198.
4. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997 Oct 25;315(7115):1096-9.
5. Kalish LM, et al. Australian Prescriber 2011;34:162-6.
6. Rosenberg J, A Rochon P, S Gill S. Unveiling a prescribing cascade in an older man. J Am Geriatr Soc. 2014 Mar;62(3):580-1. doi: 10.1111/jgs.12714. PubMed PMID: 24628637.
7. Gnjjidic D, Le Couteur DG, Hilmer SN. Discontinuing drug treatments. BMJ. 2014 Nov 21;349:g7013.
8. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011 Nov 24; 365(21):2002-12.
9. Bayoumi I, Dolovich L, Hutchison B, Holbrook A. Medication-related emergency department visits and hospitalizations among older adults. Can Fam Physician. 2014 Apr; 60(4):e217-22.

Additional References:

Frailty Assessment Links: <http://geriatricresearch.medicine.dal.ca/pdf/Clinical%20Faily%20Scale.pdf>

AGS Geriatric Evaluation and Management Tools:

<http://familymed.uthscsa.edu/gerifellowship/redirect/articles/CLC/Geriatrics%20Eval%20Management%20Tool%20for%20Frailty.pdf>

CARDIOLOGY

Antiplatelets & Anticoagulants: Dual & Triple Therapy

1. Guyatt Gordon H., Akl EA., Crowther M. *Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians (ACCP-AT9)*. Evidence-Based Clinical Practice Guidelines. *Chest* 2012; 141(2)(Suppl):7S–47S.
Lansberg MG, et al. *Antithrombotic & thrombolytic therapy for ischemic stroke: antithrombotic therapy & prevention of thrombosis, 9th ed: American College of Chest Physicians (ACCP-AT9) evidence-based guidelines*. *Chest*. 2012;141(2)(suppl):e601S-e636S.
You JJ, Singer DE, et al. *Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence(ACCP-AT9) -based clinical guidelines*. *Chest*. 2012;141(2)(suppl):e531S-575S.
Vandvik PO, Lincoff AM, Gore JM, et al. *American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines*. *Chest*. 2012 Feb;141(2 Suppl):e637S-68S.
2. Antman EM, Hand M, Armstrong PW, et al. *2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction)*. *J Am Coll Cardiol* 2007.
3. Bell Alan D., Roussin André, Cartier Raymond, et al. *The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society (CCS) Guidelines*. *Can J Cardiol*. 2011 May-Jun;27 Suppl A:S1-59
4. Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2014 Jul;45(7):2160-236.
5. Wang Y, Wang Y, Zhao X, et al; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. *N Engl J Med*. 2013 Jul 4;369(1):11-9.
6. Diener HC, Bogousslavsky J, Brass LM, et al; MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet*. 2004 Jul 24-30;364(9431):331-7.
7. Johnston SC, Easton JD, Farrant M, et al. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. *Int J Stroke*. 2013 Aug;8(6):479-83.
8. Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Han S, Lee SG, Seong IW, Rha SW, Jeong MH, Lim DS, Yoon JH, Hur SH, Choi YS, Yang JY, Lee NH, Kim HS, Lee BK, Kim KS, Lee SU, Chae JK, Cheong SS, Suh IW, Park HS, Nah DY, Jeon DS, Seung KB, Lee K, Jang JS, Park SJ. Optimal duration of dual Antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. *Circulation*. 2014 Jan 21;129(3):304-12.
9. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. *N Engl J Med*. 2014 Dec 4;371(23):2155-66.
10. Warfarin Antiplatelet Vascular Evaluation Trial Investigators (WAVE), Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, Sussex B, Liu L, Guzman R, Cina C, Crowell R, Keltai M, Gosselin G. *Oral anticoagulant and antiplatelet therapy and peripheral arterial disease*. *N Engl J Med*. 2007 Jul 19;357(3):217-27.

11. Antman EM, Hand M, Armstrong PW, et al. *2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines* (Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2007.
12. Guyatt Gordon H, Akl EA, Crowther M. *Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians (ACCP-AT9)*. Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2)(Suppl):7S–47S.
13. Bunch TJ, May HT, Bair TL, et al. Percent time with a supratherapeutic INR in atrial fibrillation patients using an antiplatelet agent is associated with long-term risk of dementia. American Heart Association 2014 Scientific Sessions; November 17, 2014; Chicago, IL. [Abstract 13426](#)
14. Bell Alan D, Roussin André, Cartier Raymond, et al. *The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society (CCS) Guidelines*. Can J Cardiol. 2011 May-Jun;27 Suppl A:S1-59.
15. Guyatt Gordon H, Akl EA, Crowther M. *Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians (ACCP-AT9)*. Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2)(Suppl):7S–47S.
16. Definition of “percutaneous coronary intervention” <http://medical-dictionary.thefreedictionary.com/percutaneous+coronary+intervention>
17. Definition of “acute coronary syndrome” <http://www.patient.co.uk/health/acute-coronary-syndrome>

Additional References:

Tanguay JF, Bell AD, Ackman ML et al. **Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy**. Can J Cardiol. 2013 Aug 23.

Dewilde WJ, Oirbans T, Verheugt FW et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial (**WOEST**). Lancet. 2013 Mar 30;381(9872):1107-15.

CARDIOLOGY

Atrial Fibrillation: Antithrombotics for Stroke Prevention

1. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. **STOPP/START** criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015 Mar;44(2):213-8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16. PubMed PMID: 25324330; PubMed Central PMCID: PMC4339726.
2. By the American Geriatrics Society 2015 **Beers** Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015 Oct 8. doi: 10.1111/jgs.13702. [Epub ahead of print] PubMed PMID: 26446832.
3. PL Detail-Document, Potentially Harmful Drugs in the Elderly: Beers List. Pharmacist's Letter/Prescriber's Letter. June 2012.
4. PL Detail-Document, STARTing and STOPping Medications in the Elderly. Pharmacist's Letter/Prescriber's Letter. September 2011.
5. Jin M, Kosar L. Atrial fibrillation. RxFiles 9th ed. Saskatoon, SK: RxFiles; 2012.
6. Kosar L, Jin M, Kamrul R, Schuster B. Oral anticoagulation in atrial fibrillation. Balancing the risk of stroke with the risk of bleed. Can Fam Physician 2012; 58:850-8.
7. **ACTIVE A** Investigators, Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009 May 14;360(20):2066-78.
8. Gillis AM, Verma A, Talajic M, Nattel S, et al. and the **CCS Atrial Fibrillation Guidelines** Committee. Society Guidelines Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm Management. Can J Cardio 2011;27:47-59.
9. Frankel G, Kamrul R, Kosar L, Jensen B. Rate versus rhythm control in atrial fibrillation. Can Fam Physician 2013;59:161-8.
10. Whitbeck MG, Charnigo RJ, Khairy P et al. Increased mortality among patients taking digoxin - analysis from the **AFFIRM** study. Eur Heart J. 2013 May;34(20):1481-8.
11. Weiss, B. Diagnostic Evaluation of Urinary Incontinence in Geriatric Patients. Am Fam Physician. 1998 Jun 1;57(11):2675-2684.
12. Giardian EG. Therapeutic use & major side effects of sotalol. UpToDate[®]. Accessed: http://www.uptodate.com/contents/therapeutic-use-and-major-side-effects-of-sotalol?source=search_result&search=sotalol+elderly+female&selectedTitle=1~150#H21
13. Verma A, Cairns JA, Mitchell LB, et al. **CCS Atrial Fibrillation Guidelines Committee**. 2014 focused update of the Canadian cardiovascular society (CCS) guidelines for the management of atrial fibrillation. Can J Cardiol. 2014 Oct; 30(10):1114-30.
14. You JJ, Singer DE, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: **American College of Chest Physicians** (ACCP-AT9) evidence -based clinical practice guidelines. Chest. 2012;141(2)(suppl):e531S-575S.
15. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the **ESC Guidelines** for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Europace. 2012 Aug 24. ESC Updated 2012 Management of Atrial Fibrillation Guidelines.
16. Camm AJ, Kirchhof P, Lip GY, et al; **European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery**. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429.
17. De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes. **ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease** position paper. J Am Coll Cardiol 2012;59:1413-25.
18. Gladstone DJ, Geerts WH, Douketis J, Ivers N, Healey JS, Leblanc K. How to Monitor Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Practice Tool Endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society. Ann Intern Med. 2015 Jun 30. doi: 10.7326/M15-0143. [Epub ahead of print] PubMed PMID: 26121536.

19. Dumont Z, Kosar L. Warfarin tips & dosing nomograms. Saskatoon, SK: RxFiles; 2013.
20. Warfarin-food interactions. Pharmacist's Letter/Prescriber's Letter 2005;21(5):210507.
21. National Institute of Health Clinical Center. Important information to know when you are taking: Warfarin (Coumadin) and Vitamin K. 2003. Available: http://www.cc.nih.gov/ccc/patient_education/drug_nutrient/coumadin1.pdf
22. Warfarin-food interactions. Pharmacist's Letter/Prescriber's Letter 2005;21(5):210507.
23. Warfarin-food interactions. Pharmacist's Letter/Prescriber's Letter 2005;21(5):210507.

Additional References:

Sardar P, Chatterjee S, Chaudhari S, et al. **New oral anticoagulants in elderly** adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014 May;62(5):857-64.

CARDIOLOGY

Atrial Fibrillation: Rate versus Rhythm Control

1. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. **STOPP/START** criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015 Mar;44(2):213-8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16. PubMed PMID: 25324330; PubMed Central PMCID: PMC4339726.
2. By the American Geriatrics Society 2015 **Beers** Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015 Oct 8. doi: 10.1111/jgs.13702. [Epub ahead of print] PubMed PMID: 26446832.
3. PL Detail-Document, Potentially Harmful Drugs in the Elderly: Beers List. Pharmacist's Letter/Prescriber's Letter. June 2012.
4. PL Detail-Document, **STARTing** and **STOPping** Medications in the Elderly. Pharmacist's Letter/Prescriber's Letter. September 2011.
5. Skanes A, Healey J, Cairns J, et al. Focused 2012 Update of the **CCS Atrial Fibrillation Guidelines**: Recommendations for Stroke Prevention and Rate/Rhythm Control. Can J Cardiol 2012; 28:125-136.
6. You JJ, Singer DE, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: **American College of Chest Physicians (ACCP-AT9)** evidence -based clinical practice guidelines. Chest. 2012;141(2)(suppl):e531S-575S.
7. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the **ESC Guidelines** for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Europace. 2012 Aug 24. ESC Updated 2012 Management of Atrial Fibrillation Guidelines.
8. Camm AJ, Kirchhof P, Lip GY, et al; **European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery**. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429.
9. De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes. **ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease** position paper. J Am Coll Cardiol 2012;59:1413-25.
10. Jin M, Kosar L. Atrial fibrillation. RxFiles 9th ed. Saskatoon, SK: RxFiles; 2012.
11. Kosar L, Jin M, Kamrul R, Schuster B. Oral anticoagulation in atrial fibrillation. Balancing the risk of stroke with the risk of bleed. Can FamPhysician 2012;58:850-8.
12. **ACTIVE A** Investigators, Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009 May 14;360(20):2066-78.
13. Dumont Z, Kosar L. Warfarin tips & dosing nomograms. Saskatoon, SK: RxFiles; 2013.
14. Gillis AM, Verma A, Talajic M, Nattel S, et al. and the **CCS Atrial Fibrillation Guidelines** Committee. Society Guidelines Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm Management. Can J Cardio 2011;27:47-59.
15. Frankel G, Kamrul R, Kosar L, Jensen B. Rate versus rhythm control in atrial fibrillation. Can Fam Physician 2013;59:161-8.
16. Whitbeck MG, Charnigo RJ, Khairy P et al. Increased mortality among patients taking digoxin - analysis from the **AFFIRM** study. Eur Heart J. 2013 May;34(20):1481-8.
17. Weiss, B. Diagnostic Evaluation of Urinary Incontinence in Geriatric Patients. Am Fam Physician. 1998 Jun 1;57(11):2675-2684.
18. Giardian EG. Therapeutic use & major side effects of sotalol. UpToDate®. Accessed: http://www.uptodate.com/contents/therapeutic-use-and-major-side-effects-of-sotalol?source=search_result&search=sotalol+elderly+female&selectedTitle=1~150#H21

CARDIOLOGY

Dyslipidemia

1. Anderson T, Gregoire J, Hegele R, et al. Society Guidelines 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. *Can J Cardiol* 2013;29:151-67
2. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. *Can J Cardiol* 2009;25(10):567-79.
3. Newson RS, Felix JF, Heeringa J, Hofman A, Wittteman JC, Tiemeier H. Association between serum cholesterol and noncardiovascular mortality in older age. *J Am Geriatr Soc*. 2011 Oct;59(10):1779-85. doi: 10.1111/j.1532-5415.2011.03593.x. Epub 2011 Sep 21. PubMed PMID: 22091490.
4. Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. *Curr Atheroscler Rep*. 2007 Nov;9(5):389-96. PubMed PMID: 18001622.
5. Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. *Arch Intern Med*. 2012 Aug 13;172(15):1180-2. doi: 10.1001/archinternmed.2012.2171. PubMed PMID: 22688574; PubMed Central PMCID: PMC4285455.
6. Lee DS, Markwardt S, Goeres L, Lee CG, Eckstrom E, Williams C, Fu R, Orwoll E, Cawthon PM, Stefanick ML, Mackey D, Bauer DC, Nielson CM. Statins and physical activity in older men: the osteoporotic fractures in men study. *JAMA Intern Med*. 2014 Aug;174(8):1263-70. doi: 10.1001/jamainternmed.2014.2266. PubMed PMID: 24911216; PubMed Central PMCID: PMC4346343.
7. Alperovitch A, Kurth T, Bertrand M, Ancelin ML, Helmer C, Debette S, Tzourio C. Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study. *BMJ*. 2015 May 19;350:h2335. doi: 10.1136/bmj.h2335. PubMed PMID: 25989805; PubMed Central PMCID: PMC4437042.
8. Savarese G, Gotto AM Jr, Paolillo S, D'Amore C, Losco T, Musella F, Scala O, Marciano C, Ruggiero D, Marsico F, De Luca G, Trimarco B, Perrone-Filardi P. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. *J Am Coll Cardiol*. 2013 Dec 3;62(22):2090-9. doi: 10.1016/j.jacc.2013.07.069. Epub 2013 Aug 28. Erratum in: *J Am Coll Cardiol*. 2014 Mar 25;63(11):1122. PubMed PMID: 23954343.
9. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. *J Am Coll Cardiol*. 2008 Jan 1;51(1):37-45. doi: 10.1016/j.jacc.2007.06.063. PubMed PMID: 18174034.
10. Toward Optimized Practice. Prevention and Management of Cardiovascular Disease Risk in Primary Care: Clinical Practice Guideline. Feb 2015. Available: http://www.topalbertadoctors.org/download/1655/Lipid%20Pathway%20CPG.pdf?_20150420112114
11. Anderson T, Gregoire J, Hegele R, et al. Society Guidelines 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. *Can J Cardiol* 2013;29:151-67
12. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. *Can J Cardiol* 2009;25(10):567-79.
13. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *BMJ* 2003;326:1423.
14. PL Detail-Document, Do Benefits of Statins Outweigh Risks in the Elderly? Pharmacist's Letter/Prescriber's Letter. February 2012.
15. Jacobs JM, Cohen A, Ein-Mor E, Stessman J. Cholesterol, statins, and longevity from age 70 to 90 years. *J Am Med Dir Assoc*. 2013 Dec;14(12):883-8.
16. Newson RS, Felix JF, Heeringa J, Hofman A, Wittteman JC, Tiemeier H. Association between serum cholesterol and noncardiovascular mortality in older age. *J Am Geriatr Soc*. 2011 Oct;59(10):1779-85. doi: 10.1111/j.1532-5415.2011.03593.x. Epub 2011 Sep 21. PubMed PMID: 22091490.
17. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C; TNT Steering Committee Members and Investigators. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? *Am J Cardiol*. 2004 Jan 15;93(2):154-8. PubMed PMID: 14715339.

18. Redberg RF. Statins and weight gain. *JAMA Intern Med.* 2014 Jul;174(7):1046. doi: 10.1001/jamainternmed.2014.1994. PubMed PMID: 24763439.
19. Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. *J Gerontol A Biol Sci Med Sci.* 2007 Aug;62(8):879-87. Review. PubMed PMID: 17702880.
20. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. *Circulation* 2002;106:1024-8.
21. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. *Cochrane Database Syst Rev* 2009;2:CD003160.
22. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. *Pharmacotherapy* 2003;23:871-80.
23. Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, Trikalinos TA. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. *J Gen Intern Med.* 2015 Mar;30(3):348-58. doi: 10.1007/s11606-014-3115-3. Epub 2015 Jan 10. PubMed PMID: 25575908; PubMed Central PMCID: PMC4351273.
24. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. *Pharmacotherapy* 2009;29:800-11.
25. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. *Pharmacotherapy* 2003;23:1663-7.
26. Strom BL, Schinnar R, Karlawish J, Hennessy S, Teal V, Bilker WB. Statin Therapy and Risk of Acute Memory Impairment. *JAMA Intern Med.* 2015 Jun 8. doi: 10.1001/jamainternmed.2015.2092. [Epub ahead of print] PubMed PMID: 26054031.
27. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, Lafrance JP, Levy A, Garg AX, Ernst P; Canadian Network for Observational Drug Effect Studies. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. *BMJ.* 2013 Mar 18;346:f880.
28. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, De Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet* 2010;375:735-42.
29. Anderson T, Gregoire J, Hegele R, et al. Society Guidelines 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. *Can J Cardiol* 2013;29:151-67
30. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. *Can J Cardiol* 2009;25(10):567-79.
31. PL Detail-Document, Clinically Significant Statin Drug Interactions. *Pharmacist's Letter/Prescriber's Letter.* April 2012.
32. Anderson TJ, Grégoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society (CCS) guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. *Can J Cardiol.* 2013 Feb;29(2):151-67.
33. Kutner JS, Blatchford PJ, Taylor DH Jr, Ritchie CS, Bull JH, Fairclough DL, Hanson LC, LeBlanc TW, Samsa GP, Wolf S, Aziz NM, Currow DC, Ferrell B, Wagner-Johnston N, Zafar SY, Cleary JF, Dev S, Goode PS, Kamal AH, Kassner C, Kvale EA, McCallum JG, Ogunseitan AB, Pantilat SZ, Portenoy RK, Prince-Paul M, Sloan JA, Swetz KM, Von Gunten CF, Abernethy AP. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. *JAMA Intern Med.* 2015 May 1;175(5):691-700. doi: 10.1001/jamainternmed.2015.0289. PubMed PMID: 25798575.

CARDIOLOGY

Heart Failure (Systolic)

1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013 Oct 15;62(16):e147-239.
2. ***PL Detail-Document, Toolbox for Improving Heart Failure Care. Pharmacist's Letter/Prescriber's Letter. November 2013.***
3. Alosa Foundation. A Guide to Outpatient Management of Congestive Heart Failure. Nov 2011. Available: http://www.alosafoundation.org/wp-content/uploads/2013/08/CHF_EvDoc.pdf
4. Durso SC, Sullivan GM, American Geriatrics Society. Geriatrics review syllabus a core curriculum in geriatric medicine. New York: American Geriatrics Society; 2013.
5. American Heart Association. Classes of Heart Failure. Aug 2011. Available: [http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure UCM 306328 Article.jsp](http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp)
6. Iltis GB, Rabelo ER, Clausell N, Rohde LE, Biolo A, Beck-da-Silva L. Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical trial. *JAMA Intern Med*. 2013 Jun 24;173(12):1058-64.
7. Petrone AB, Gaziano JM, Djoussé L. Alcohol consumption and risk of death in male physicians with heart failure. *Am J Cardiol*. 2014 Oct 1;114(7):1065-8. doi: 10.1016/j.amjcard.2014.07.021. Epub 2014 Jul 18. PubMed PMID: 25129877; PubMed Central PMCID: PMC4163088.
8. ***PL Detail-Document, Toolbox for Improving Heart Failure Care. Pharmacist's Letter/Prescriber's Letter. November 2013.***
9. ***PL Detail-Document, Heart Failure Treatment at a Glance. Pharmacist's Letter/Prescriber's Letter. November 2013.***
10. Durso SC, Sullivan GM, American Geriatrics Society. Geriatrics review syllabus a core curriculum in geriatric medicine. New York: American Geriatrics Society; 2013.
11. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013 Oct 15;62(16):e147-239.
12. ***PL Detail-Document, Toolbox for Improving Heart Failure Care. Pharmacist's Letter/Prescriber's Letter. November 2013.***
13. ***PL Detail-Document, Target Doses of Meds for Systolic Heart Failure. Pharmacist's Letter/Prescriber's Letter. November 2013.***
14. Hunt SA, Abraham WT, Chin MH, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the
15. Independent Drug Information Service. Helping the failing heart: Safe and effective CHF management. Available: http://www.alosafoundation.org/wp-content/uploads/2013/08/CHF_UnAd.pdf
16. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013 Oct 15;62(16):e147-239.
17. ***PL Detail-Document, Toolbox for Improving Heart Failure Care. Pharmacist's Letter/Prescriber's Letter. November 2013.***
18. RxFiles BETA-BLOCKER (BB): Comaprison Chart. *RxFiles Drug Comparison Chart*. Accessed 01 Aug 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-HTN-bb.pdf>
19. Lanier JB, Mote MB, Clay EC. *Evaluation and management of orthostatic hypotension*. *Am Fam Physician*. 2011 Sep 1;84(5):527-36.

CARDIOLOGY

Hypertension

1. Canadian Hypertension Education Program [website]. CHEP 2014 Hypertension Recommendations. Available from: http://www.hypertension.ca/images/CHEP_2014/2014_CompleteCHEPRecommendations_EN_HCP1009.pdf , Accessed 28Feb14. Dasgupta K, Quinn RR, Zarnke KB, et al. Canadian Hypertension Education Program. The **2014 CHEP-Canadian Hypertension** Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol. 2014 May;30(5):485-501.
2. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug;5(4):259-352. doi: 10.1016/j.jash.2011.06.001. Review. PubMed PMID: 21771565.
3. Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, Sanchez E. An effective approach to high blood pressure control: a science advisory from the american heart association, the american college of cardiology, and the centers for disease control and prevention. Hypertension. 2014 Apr;63(4):878-85. doi: 10.1161/HYP.000000000000003. Epub 2013 Nov 15. PubMed PMID: 24243703.
4. Task Force for the management of arterial hypertension of the European Society of Hypertension; Task Force for the management of arterial hypertension of the European Society of Cardiology. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. Blood Press. 2013 Aug;22(4):193-278. doi: 10.3109/08037051.2013.812549. Epub 2013 Jun 18. PubMed PMID: 23777479.
5. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427. PubMed PMID: 24352797.
6. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe O, Oparil S, White WB; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Soc Hypertens. 2015 Jun;9(6):453-98. doi: 10.1016/j.jash.2015.03.002. Epub 2015 Mar 31. PubMed PMID: 25840695.
7. Egan, B. *Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension*. Accessed at UpToDate 01 Aug 2013. (Literature review current through: Jun 2013. Topic last updated: Jan 30, 2013)
8. Canadian Hypertension Education Program [website]. *Accurate measurement of blood pressure*. Markham, ON: Hypertension Canada; 2011. Available from: www. http://www.hypertension.ca/images/2013_EducationalResources/2013_MeasureBPPoster_EN_HCP1040.pdf. Accessed 18Nov13
9. Lamb TS, Thakrar A, Ghosh M, Wilson M, Wilson TW. 2010. Comparison of two oscillometric blood pressure monitors in subjects with atrial fibrillation. Clinical and Investigative Medicine 33: E54-62.
10. Appel LJ, Espeland MA, Easter L, et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med. 2001;161:685-93
11. Canadian 2013 Guidelines (April 2013): <http://guidelines.diabetes.ca/>
12. ADA 2013: American Diabetes Association. Clinical practice recommendations. Diabetes Care 2013; 36:S1-S110. http://care.diabetesjournals.org/content/36/Supplement_1.toc
13. Banach M, Aronow WS. Blood pressure j-curve: current concepts. Curr Hypertens Rep. 2012 Dec;14(6):556-66. doi: 10.1007/s11906-012-0314-3.

14. Bakris GL, Kaplan NM, Forman JP. Management of severe asymptomatic hypertension (hypertensive urgencies). 2012. Available from: www.uptodate.com.
15. Benetos A, Labat C, Rossignol P, Fay R, Rolland Y, Valbusa F, Salvi P, Zamboni M, Manckoundia P, Hanon O, Gautier S. Treatment With Multiple Blood Pressure Medications, Achieved Blood Pressure, and Mortality in Older Nursing Home Residents: The PARTAGE Study. *JAMA Intern Med*. 2015 Jun;175(6):989-95. doi: 10.1001/jamainternmed.2014.8012. PubMed PMID: 25685919.
16. Mossello E, Pieraccioni M, Nesti N, Bulgaresi M, Lorenzi C, Caleri V, Tonon E, Cavallini MC, Baroncini C, Di Bari M, Baldasseroni S, Cantini C, Biagini CA, Marchionni N, Ungar A. Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs. *JAMA Intern Med*. 2015 Apr;175(4):578-85. doi: 10.1001/jamainternmed.2014.8164. PubMed PMID: 25730775.
17. RxFiles *ORAL ANTIHYPERTENSIVES Summary/Guidelines Comparison Chart, RxFiles Drug Comparison Chart*. Accessed 08 November 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/cht-HTN-1page%20summary.pdf>
18. RxFiles *ACE INHIBITOR (ACEI)/ ANGIOTENSIN II RECEPTOR BLOCKER (ARB): Comparison Chart. RxFiles Drug Comparison Chart*. Accessed 08 November 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-HTN-ace-arb.pdf>
19. RxFiles *BETA-BLOCKER (BB): Comparison Chart. RxFiles Drug Comparison Chart*. Accessed 01 Aug 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-HTN-bb.pdf>
20. RxFiles *CALCIUM CHANNEL BLOCKER (CCB): Comparison Chart. RxFiles Drug Comparison Chart*. Accessed 08 November 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-HTN-ccb.pdf>
21. RxFiles *THIAZIDE Like DIURETICS. RxFiles Drug Comparison Chart*. Accessed 08 November 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-HTN-diuretics.pdf>
22. Wright JM, Musini VM. First-line drugs for hypertension. *Cochrane Database Syst Rev*. 2009 Jul 8;(3):CD001841.
23. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2013;(). doi:10.1001/jama.2013.284427.
24. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. *Hypertension*. 2012 Jun;59(6):1110-7.
25. Dhalla IA, Gomes T, Yao Z, Nagge J, Persaud N, Hellings C, Mamdani MM, Juurlink DN. Chlorthalidone versus ydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. *Ann Intern Med*. 2013 Mar 19;158(6):447-55.
26. Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. *Am J Hypertens*. 2001 Sep;14(9 Pt 1):963-8. PubMed PMID: 11587165.
27. Hackam DG, Quinn RR, Ravani P, et al. Canadian Hypertension Education Program. *The 2013 Canadian Hypertension Education Program (CHEP) Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension*. *Can J Cardiol*. 2013 Mar 28.
28. *BETA-BLOCKER (BB): Comparison Chart. RxFiles Drug Comparison Chart*. Accessed 01 Aug 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-HTN-bb.pdf>
29. Schumann S, Hickner J. When not to use beta-blockers in seniors with hypertension. *J Fam Pract*. 2008 Jan;57(1):18-21.
30. Kuyper LM, Khan NA. **Atenolol vs Nonatenolol** β -Blockers for the Treatment of Hypertension: A Meta-analysis. *Can J Cardiol*. 2014 May;30(5S):S47-S53.
31. Hackam DG, Quinn RR, Ravani P, et al. Canadian Hypertension Education Program. *The 2013 Canadian Hypertension Education Program (CHEP) Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension*. *Can J Cardiol*. 2013 Mar 28.
32. RxFiles *BETA-BLOCKER (BB): Comparison Chart. RxFiles Drug Comparison Chart*. Accessed 01 Aug 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-HTN-bb.pdf>

33. Franklin SS, Gokhale SS, Chow VH, Larson MG, Levy D, Vasan RS, Mitchell GF, Wong ND. Does low diastolic blood pressure contribute to the risk of recurrent hypertensive cardiovascular disease events? The Framingham Heart Study. *Hypertension*. 2015 Feb;65(2):299-305. doi: 10.1161/HYPERTENSIONAHA.114.04581. Epub 2014 Nov 24. PubMed PMID: 25421982.
34. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; the VA NEPHRON-D Investigators. Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy. *N Engl J Med*. 2013 Nov 9. [Epub ahead of print] PubMed PMID: 24206457.
35. RxFiles Trial Summary. ACCOMPLISH 1,2: ACEI + Amlodipine vs ACEI + Hydrochlorothiazide in High Risk Hypertensives. Accessed on-line 5 December 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/HTN-QandA-Accomplish.pdf>
36. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Physicians; American Association for Thoracic Surgery; Preventive Cardiovascular Nurses Association; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2012 Dec 18;60(24):e44-e164. doi: 10.1016/j.jacc.2012.07.013. Epub 2012 Nov 19.
37. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate (20-40mg tid) and hydralazine (37.5-75mg tid) in blacks with heart failure (**A-HeFT**). *N Engl J Med*. 2004 Nov 11;351(20):2049-57.
38. Diagnosis and Management of Chronic **Heart Failure** in the Adult: **ACC/AHA 2005 Guideline Update** for the (J Am Coll Cardiol 2005) <http://www.acc.org/clinical/guidelines/failure/index.pdf> (**European 2005** Chronic Heart failure guidelines <http://www.escardio.org/NR/rdonlyres/8A2848B4-5DEB-41B9-9A0A-5B5A90494B64/0/CHFFullTextehi205FVFW170505.pdf>)
39. PL Detail-Document, The "Triple Whammy." Pharmacist's Letter/Prescriber's Letter. April 2013
40. Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis. *Am J Hypertens*. 2013 Mar;26(3):424-41.
41. Bakris GL, Kaplan NM, Forman JP. Management of severe asymptomatic hypertension (hypertensive urgencies). 2012. Available from: www.uptodate.com.
42. Marik PE, Varon J. Hypertensive crises: challenges and management. *Chest*. 2007 Jun;131(6):1949-62. full-text, correction can be found in *Chest* 2007 Nov;132(5):1721.
43. Lanier JB, Mote MB, Clay EC. Evaluation and management of orthostatic hypotension. *Am Fam Physician*. 2011 Sep 1;84(5):527-36.
44. Shihao C, Lipsitz LA, Biaggioni I. ASH position paper: evaluation and treatment of orthostatic hypotension. *J Clin Hypertens (Greenwich)*. 2013 Mar;15(3):147-53.
45. Lanier JB, Mote MB, Clay EC. Evaluation and management of orthostatic hypotension. *Am Fam Physician*. 2011 Sep 1;84(5):527-36.
46. Masaki KH, Schatz IJ, Burchfiel CM, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. *Circulation*. 1998;98:2290-5.
47. Podoleanu C, Maggi R, Brignole M, et al. Lower limb and abdominal compression bandages prevent progressive orthostatic hypotension in elderly persons: a randomized single-blind controlled study. *J Am Coll Cardiol*. 2006;48(7):1425-1432.
48. Bird ST, Delaney JA, Brophy JM, Etminan M, Skeldon SC, Hartzema AG. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. *BMJ*. 2013 Nov 5;347:f6320. doi: 10.1136/bmj.f6320. PubMed PMID: 24192967; PubMed Central PMCID: PMC3817852.

49. Shannon JR, Diedrich A, Biaggioni I, Tank J, Robertson RM, Robertson D, Jordan J. Water drinking as a treatment for orthostatic syndromes. *Am J Med.* 2002 Apr 1;112(5):355-60
50. Jordan J, Shannon JR, Grogan E, et al. A potent pressor response elicited by drinking water. *Lancet.* 1999;353:723.
51. ALLHAT Working Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA.* 2002;288:2981-2997.
52. RxFiles *BETA-BLOCKER (BB): Comparison Chart.* RxFiles Drug Comparison Chart. Accessed 01 Aug 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-HTN-bb.pdf>
53. Carlberg B, Samuelsson O, Lindholm LH. *Atenolol in hypertension: is it a wise choice?* *Lancet.* 2004 Nov 6;364(9446):1684-9.
54. Weiss, B. *Diagnostic Evaluation of Urinary Incontinence in Geriatric Patients.* *Am Fam Physician.* 1998 Jun 1;57(11):2675-2684.
55. Gurwitz JH et al. *Thiazide diuretics and the initiation of anti-gout therapy.* *Journal of Clinical Epidemiology;* 1997 50:953-57.
56. Gurwitz JH, Kalish SC, Bohn RL et al. *Thiazide Diuretics and the Initiation of Anti-Gout Therapy.* *Journal of Clinical Epidemiology.* 1997 Aug;50(8):953-9
57. RxFiles *The Gout – Q&A & Treatment Options.* RxFiles Drug Comparison Chart. Accessed 01 Aug 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-Gout.pdf>
58. Sterns, R. *Diuretics and calcium balance.* Accessed at Up-to-Date 01 Aug 2013. (Literature review current through: Jun 2013. Topic last updated: Jul 16, 2012).
59. Up-to-Date <http://www.uptodate.com/contents/hydrochlorothiazide-drug-information?source=preview&anchor=F179606&selectedTitle=4~150#F179606>

Additional References:

Tinetti ME, Han L, Lee DS, McAvay GJ, Peduzzi P, Gross CP, Zhou B, Lin H. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. *JAMA Intern Med.* 2014 Apr;174(4):588-95. doi: 10.1001/jamainternmed.2013.14764. PubMed PMID: 24567036.

Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. *JAMA.* 2014 Jun 4;311(21):2216-24.

Trial name	Reference & Notes
AASK	Wright JT Jr, Bakris G, Greene T, Agodoa LY, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial .; African American Study of Kidney Disease and Hypertension Study Group. JAMA 2002;288:2421-31.
ACCOMPLISH	Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. (ACCOMPLISH) N Engl J Med. 2008 Dec 4;359(23):2417-2428.
ACCORD-BP	ACCORD Study Group, Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med 2010 0: NEJMoa1001286.
A-HeFT	Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate (20-40mg tid) and hydralazine (37.5-75mg tid) in blacks with heart failure (A-HeFT). N Engl J Med. 2004 Nov 11;351(20):2049-57
ALLHAT	ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel block vs. diuretic. JAMA. 2002;288:2981-2997.
ALTITUDE	Parving HH, Brenner BM, McMurray JJ, et al; the ALTITUDE Investigators. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes . N Engl J Med. 2012 Nov 3
CATIS	He J, Zhang Y, Xu T, et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014 Feb 5;311(5):479-89. doi: 10.1001/jama.2013.282543. PubMed PMID: 24240777.
CHARM	1: Pfeffer MA, Swedberg K, Granger CB, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003 Sep 6;362(9386):759-66. 2: Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003 Sep 6;362(9386):772-6. 3: McMurray JJ, Ostergren J, Swedberg K, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003 Sep 6;362(9386):767-71.
COMET	Cleland JG, et al. COMET Investigators. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). J Am Coll Cardiol. 2006 Apr 18;47(8):1603-11.
HOPE	Yusuf S, Sleight P, Pogue J, Bosch J, et al. The Heart Outcomes Prevention Evaluation (HOPE) Study. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular & microvascular outcomes in people with <u>diabetes mellitus</u> : results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9. Bosch J, Yusuf S, Pogue J, Sleight P et al . Use of ramipril in <u>preventing stroke</u> : double blind randomised trial.; HOPE Investigators. Heart outcomes prevention evaluation. BMJ 2002;324:699-702.
HYVET	NS, Peters R, Fletcher AE, Staessen JA, Liu L, et al.; the HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med. 2008 Mar 31; [Epub ahead of print]
IDNT	Lewis EJ, Hunsicker LG, Clarke WR, Berl T et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes (IDNT); Collaborative Study Group. N Engl J Med 2001 Sep 20;345(12):851-60.
INTERACT2	
LIFE	Dahlof B, Devereux RB, Kjeldsen SE, Julius S et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in <u>hypertension study (LIFE)</u> : a randomised trial against atenolol. Lancet 2002;359:995-1003. Lindholm LH, Ibsen H, Dahlof B, Devereux RB et al. Cardiovascular morbidity and mortality in patients with <u>diabetes</u> in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10. (Note: in patients with left ventricular hypertrophy). Kjeldsen SE, Dahlof B, Devereux RB, Julius S et al. Effects of losartan on cardiovascular morbidity and mortality in patients with <u>isolated systolic hypertension</u> and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491-8.
NORDIL	Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.
ONTARGET	Yusuf S, Teo KK, Pogue J, et al for the ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559
PROGRESS	PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41. Arima H, Anderson C, Omae T, et al; for the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) Collaborative Group. Effects of Blood Pressure Lowering on Intracranial and Extracranial Bleeding in Patients on Antithrombotic Therapy: The PROGRESS Trial. Stroke. 2012 Jun;43(6):1675-1677.
RENAAL	Brenner BM, Cooper ME, de Zeeuw D, Keane et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy; RENAAL Study Investigators. N Engl J Med 2001;345:861-9.
SHEP	SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in <u>older persons with isolated systolic hypertension</u> . Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991 Jun 26;265(24):3255-64. Curb JD, Pressel SL, Cutler JA, Savage PJ et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older <u>diabetic</u> patients with isolated systolic hypertension (SHEP). JAMA 1996;276:1886-92. Kostis JB, Wilson AC, et al.; SHEP Collaborative Research Group. Long-term effect (14.3 yrs) of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005 Jan 1;95(1):29-35. Kostis JB, Cabrera J, Cheng JQ, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival (SHEP). JAMA. 2011 Dec 21;306(23):2588-93. In the SHEP trial, treatment of isolated systolic hypertension with chlorthalidone stepped-care therapy for 4.5 years was associated with <u>longer life expectancy at 22 years of follow-up</u> .
SPS3	SPS3 Study Group. Blood-pressure targets in patients with recent <u>lacunar stroke</u> : the SPS3 randomised trial. Lancet 2013; published online May 29. http://dx.doi.org/10.1016/S0140-6736(13)60852-1.
Val-HeFT	Cohn JN, Tognoni G . A randomized trial of the angiotensin-receptor blocker <u>valsartan in chronic heart failure (Val-HeFT)</u> ; Valsartan Heart Failure Trial Investigators. N Engl J Med 2001;345:1667-75. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure <u>not receiving angiotensin-converting enzyme inhibitors</u> . Val-HeFT Investigators (Valsartan Heart Failure Trial). J Am Coll Cardiol 2002;40:1414-21. Anand IS, Bishu K, Rector TS, et al. Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure. Circulation. 2009 Oct 5.
VA NEPHRON-D	Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. (VA Nephron-D) N Engl J Med 2013. DOI: 10.1056/NEJMoa1303154.

CARDIOLOGY

QT Prolongation & Torsades de Pointes: Drugs & Sudden Death

1. Wolbrette D. Drugs that cause TdP & increase the risk of sudden cardiac death. *Curr Card Reports* 2004; 6: 379-84.
2. Wojciech Z & Lin D. Antipsychotic drugs and QT interval prolongation. *Psychiatr Q* 2003; 74(3): 291-306.
3. Taylor D. Antipsychotics and QT prolongation. *Acta Psychiatr Scand* 2003;107:85-95.
4. Vieweg W. New generation antipsychotic drugs and QTc interval prolongation. *Prim Care Companion J Clin Psychiatry* 2003;5 (5):205-15.
5. Roden D. Drug-induced prolongation of the QT interval. *N Engl J Med* 2004; 350: 1013-22.
6. Crouch M et al. Clinical relevance & management of drug-related QT interval prolongation. *Pharmacotherapy* 2003; 23(7):881-908.
7. Witchel H et al. Psychotropic drugs, cardiac arrhythmia, & sudden death. *J Clin Psychopharmacol* 2003; 23(1):58-77.
8. Brown et al. Cardiovascular effects of anti-psychotics. *Clin Pharmacokinet* 2004; 43(1): 38-56 (see Roden NEJM'08)
9. Gowda RM, et al. Torsade de pointes: the clinical considerations. *Int J Cardiol.* 2004;96:1
10. Sudden Arrhythmia Death Syndromes Foundation The long QT syndrome. SADS Foundation
11. <http://www.sads.org/LQTFlyer.pdf> (Cardiac Arrhythmia Research & Education Foundation www.longqt.org)
12. Ray WA, et al. Oral erythromycin & the risk of sudden death from cardiac causes. *N Engl J Med.* 2004 Sep 9;351(11):1089-96.
13. Liu BA, Juurlink DN. Drugs and the QT interval - caveat doctor. *N Engl J Med.* 2004 Sep 9;351(11):1053-6.
14. Woeffel JA. Drug-Induced Long QT Interval & Sudden Cardiac Death. *Pharmacist's Letter* Nov 2004;20:201111
15. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. *JAMA.* 2003 Apr 23-30;289(16):2120-7. Review. Erratum in: *JAMA.* 2003 Sep 10;290(10):1318.
17. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. *J Am Coll Cardiol.* 2010 Feb 9;55(6):515-25.
18. Aström-Lilja et al. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. *Pharmacoepidemiol Drug Saf.* 2008 Jun;17(6):587-92.

Additional References:

- Abrams DJ, Perkin MA, Skinner JR. Long QT syndrome. *BMJ.* 2010 Jan 8;340:b4815. doi: 10.1136/bmj.b4815.
- Abrams DJ, Macrae CA. Long QT Syndrome. *Circulation.* 2014 Apr 8;129(14):1524-9.
- AHA/ACCF-Prevention of Torsade de Pointes in Hospital Settings, Scientific Statement From American Heart Association and the American College of Cardiology Foundation. 2010. <http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.109.192704>
- Arking DE, Pfeufer A, Post W, et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. *Nat Genet* 2006; DOI: 10.1038/ng1790. Available at: <http://www.nature.com/ng>.
- Barsheshet A, Goldenberg I, O-Uchi J, et al. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to Beta-blocker therapy in type 1 long-QT syndrome. *Circulation.* 2012;125:1988 –1996.
- Basavarajaiah S, Wilson M, Whyte G, et al. Prevalence and significance of an isolated long QT interval in elite athletes. *Eur Heart J.* 2007 Dec;28(23):2944-9. Epub 2007 Oct 18. The prevalence of prolonged QTc in elite athletes is 0.4%. A QTc of >500ms is highly suggestive of LQTS. A QTc of <500 ms in the absence of symptoms or familial disease is unlikely to represent LQTS in elite athletes.
- Bibian C, Quilez RM, Gil J et al. Clinical Relevance Of The (S)-Citalopram-Omeprazole Interaction In Geriatric Patients. *Br J Clin Pharmacol.* 2013 Aug 7.
- Blaufox AD, Tristani-Firouzi M, Seslar S, et al. Congenital Long QT 3 in the Pediatric Population. *Am J Cardiol.* 2012 Feb 21.

Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic Interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: randomized, placebo-controlled, double-blind, crossover study. *Br J Clin Pharmacol* 2012;73:411–21.

Buber J, Mathew J, Moss AJ, et al. Risk of Recurrent Cardiac Events After Onset of Menopause in Women With Congenital Long-QT Syndrome Types 1 and 2. *Circulation*. 2011 Jun 21;123(24):2784-91.

Calver L, Isbister GK. High dose droperidol and QT prolongation: analysis of continuous 12-lead recordings. *Br J Clin Pharmacol*. 2013 Oct 30.

Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. *J Am Coll Cardiol*. 2012;60:2092–2099.

Chugh SS, Reinier K, Singh T, Uy-Evanado A, Socoteanu C, Peters D, Mariani R, Gunson K, Jui J. Determinants of Prolonged QT Interval and Their Contribution to Sudden Death Risk in Coronary Artery Disease. The Oregon Sudden Unexpected Death Study. *Circulation*. 2009 Jan 26. [Epub ahead of print] Diabetes mellitus and QTc-affecting drugs determined QTc prolongation and were predictors of SCD in coronary artery disease. However, idiopathic abnormal QTc prolongation was associated with 5-fold increased odds of SCD. A continued search for novel determinants of QTc prolongation such as genomic factors is likely to enhance risk stratification for SCD in coronary artery disease.

Crotti L, Tester DJ, et al. Long QT syndrome-associated mutations in intrauterine fetal death. *JAMA*. 2013 Apr 10;309(14):1473-82.

Cuneo BF, Strasburger JF, Yu S, Horigome H et al. In Utero Diagnosis of Long QT Syndrome by Magnetocardiography. *Circulation*. 2013 Nov 12;128(20):2183-91.

Darpö B, Sager P, Macconell L et al. Exenatide at Therapeutic and Supratherapeutic Concentrations Does Not Prolong the QTc Interval in Healthy Subjects. *Br J Clin Pharmacol*. 2012 Aug 10.

Darpo B, Garnett C. Early QT assessment - how can our confidence in the data be improved? *Br J Clin Pharmacol*. 2012 Dec 24.

Darpo B, Karnad DR, Badilini F, et al. Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modeling in a Phase 1 study with oral rac-sotalol. *Br J Clin Pharmacol*. 2013 Jul 2.

Davy M, Upward J, Arumugham T, et al. Cardiac Repolarization With Gabapentin Enacarbil in a Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Thorough QT/QTc Study in Healthy Adults. *Clin Ther*. 2013 Nov 27.

Dickstein LP, Franco KN, Rome ES, et al. Recognizing, managing medical consequences of eating disorders in primary care. *Cleve Clin J Med*. 2014 Apr;81(4):255-63.

Djeddi D, Kongolo G, Lefaix C, Mounard J, Léké A. Effect of domperidone on QT interval in neonates. *J Pediatr*. 2008 Nov;153(5):663-6. Epub 2008 Jun 27. This study shows a significant association between oral domperidone therapy and QTc prolongation. Two risk factors identified: advanced gestational age & serum potassium at the upper limit of normal.

Ehret GB, et al. Drug-Induced Long QT Syndrome in Injection Drug Users Receiving Methadone: High Frequency in Hospitalized Patients and Risk Factors. *Arch Intern Med*. 2006 Jun 26;166(12):1280-7.

FDA Feb/10 notified healthcare professionals and patients that it is reviewing clinical trial data about a potentially serious effect on the heart from the use of Invirase (saquinavir) in combination with Norvir (ritonavir), antiviral medications given together to treat HIV infection. The data suggest that together the two drugs may affect the electrical activity of the heart, known as prolonged QT or PR intervals.

FDA Nov/10 is requesting that manufacturers of the painkiller propoxyphene pull the drug from the market because of concerns over cardiotoxicity. (Propoxyphene is marketed alone as Darvon & combined with acetaminophen as Darvocet.) The agency's request is based on data showing that, even when taken at therapeutic doses, the drug can lead to potentially dangerous changes in the heart's electrical activity, including prolonged PR & QT intervals & widened QRS complex. FDA advises clinicians to stop prescribing propoxyphene and to ask current users to discontinue the drug. FDA's MedWatch alert

FDA Dec/10 The injectable form of dolasetron mesylate (Anzemet) should not be used to prevent nausea or vomiting related to chemotherapy because the drug increases the risk for torsade de pointes, the FDA announced on Friday. The FDA recommends against using Anzemet injections in patients with

congenital long-QT syndrome. The warning does not apply to Anzemet tablets because the risks for developing an abnormal heart rhythm are not as high as with the injections. FDA MedWatch alert (Free)

FDA July/11 FDA has added a warning to the label of the atypical antipsychotic quetiapine (Seroquel) cautioning about potential increases in the QT interval. Postmarketing cases of QT prolongation have been reported in some 17 patients, according to the New York Times. These patients had overdosed on quetiapine, had other illnesses, or were taking other medications that can cause electrolyte imbalance or QT prolongation.

FDA Aug/11 The antidepressant citalopram (marketed as Celexa) should not be prescribed at doses above 40 mg/day because higher dosages can cause arrhythmias, the FDA has warned.

FDA Sep/11 The U.S. Food and Drug Administration (FDA) is informing the public of an ongoing safety review of the anti-nausea drug Zofran (ondansetron, ondansetron hydrochloride and their generics). Ondansetron may increase the risk of developing abnormal changes (QT prolongation & torsades) in the electrical activity of the heart.

FDA July/12 Alerting clinicians that a single 32-mg intravenous dose of ondansetron (Zofran and generics) may lead to QT interval prolongation, which in turn may put patients at risk for torsades de pointes.

FDA Dec/12 is working with the manufacturers of all 32 mg dose Ondansetron Injectable Products (brand and generic) to voluntarily recall them from the market due to QT serious cardiac toxicity.

FDA Mar/13 is warning the public that azithromycin (Zithromax or Zmax) can cause abnormal changes in the electrical activity of the heart that may lead to a potentially fatal irregular heart rhythm. Patients at particular risk for developing this condition include those with known risk factors such as existing QT interval prolongation, low blood levels of potassium or magnesium, a slower than normal heart rate, or use of certain drugs used to treat abnormal heart rhythms, or arrhythmias.

Funk KA, Bostwick JR. A Comparison of the Risk of QT Prolongation Among SSRIs. *Ann Pharmacother.* 2013 Oct;47(10):1330-41.

Health Canada Aug/10 Droperidol Injection USP is associated with severe arrhythmia (eg. QT) and the Canadian Monograph of this product has been updated to reflect this risk.

Health Canada Nov/10 Darvon-N (dextropropoxyphene) - Recall and Withdrawal in Canada - Paladin Labs Inc. Paladin Labs Inc. in collaboration with Health Canada would like to inform healthcare professionals of the voluntary recall and withdrawal of the opioid analgesic Darvon-N (dextropropoxyphene) in Canada. (widen the QRS complex, prolong the QT interval and therefore increase the risk of serious abnormal heart rhythms.)

Health Canada Feb/12 has recently approved vandetanib (CAPRELSA) to treat medullary thyroid cancer in adult patients where either the tumour cannot be removed by surgery or it has spread from the thyroid gland to other parts of the body. CAPRELSA can cause serious QT heart rhythm changes which may result in sudden death, if left untreated.

Health Canada Mar/12: Domperidone should be used at the lowest possible dose. The risk of serious ventricular arrhythmias and sudden cardiac death may be higher in patients taking daily doses greater than 30 mg, and in patients over 60 years old.

Health Canada Oct/12: Ondansetron can cause a dose-dependent prolongation of the electrocardiographic-corrected QT interval (QTc), which can lead to Torsade de Pointes, a potentially life-threatening heart rhythm abnormality. The new maximum recommended single intravenous (IV) dose of ZOFRAN[®] is 16 mg infused over 15 minutes.

Health Canada Oct/13 has completed a safety review of the drug Sensipar (cinacalcet) that identified a possible link between the drug and abnormal heart rhythm (QT) associated with low blood calcium.

Health Canada Feb/14: TELZIR (fosamprenavir) should not be used with the antiarrhythmic drugs amiodarone, lidocaine (systemic), or quinidine, as this may cause serious and/or life-threatening reactions such as abnormal heart rhythm (arrhythmias). In addition, Telzir should not be used with delavirdine, another antiviral drug to treat HIV, because it may reduce the effectiveness of delavirdine.

Health Canada Mar/14: REMERON / REMERON RD (mirtazapine) – Abnormal Heart Rhythm - Merck Canada Inc. Cases of abnormal heart rhythm (eg. QT prolongation) have been reported with the antidepressant REMERON / REMERON RD (mirtazapine) mainly with drug overdose or when taking other drugs known to cause heart rhythm problems. The product information has been updated.

Hough DW, Natarajan J, Vandebosch A, et al. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. *Int Clin Psychopharmacol*. 2010 Sep 28.

Hunt K, Hughes CA, Hills-Nieminen C. Protease Inhibitor-Associated QT Interval Prolongation. *Ann Pharmacother*. 2011 Dec;45(12):1544-50.

Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. *Br J Clin Pharmacol*. 2012 Nov 20.

Jackson H, Huisman LA, Sanatani S, Arbour LT. Long QT syndrome. *CMAJ*. 2011 Aug 9;183(11):1272-5.

Johnson JN, Ackerman MJ. Competitive sports participation in athletes with congenital long QT syndrome. *JAMA*. 2012 Aug 22;308(8):764-5.

Kao WHL, Arking DE, Post W, et al. Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community-based populations. *Circulation* 2009; 119:940-951.

Katz DF, Sun J, Khatri V, et al. QTc Interval Screening in an Opioid Treatment Program. *Am J Cardiol*. 2013 Jun 29.

Kaufman ES, McNitt S, Moss AJ, Zareba W, et al. Risk of death in the long QT syndrome when a sibling has died. *Heart Rhythm*. 2008 Jun;5(6):831-6. Epub 2008 Mar 4.

Kempsford R, Allen A, Kelly K, et al. A Repeat-dose Thorough QT Study of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI) Combination in Healthy Subjects. *Br J Clin Pharmacol*. 2013 Oct 4.

Kleiman RB, Shah RR, Morganroth J. Replacing the Thorough QT Study: Reflections of a baby in the bath water. *Br J Clin Pharmacol*. 2013 Nov 29

Kori S, Kellerman DJ, Voloshko P, Haugen G. Effects of a Supratherapeutic Dose of Investigational Orally Inhaled Dihydroergotamine (MAP0004) on QT Interval: A Randomized, Double-Blind, Active- and Placebo-Controlled Crossover Study in Healthy Volunteers. *Clin Ther*. 2012 Aug 20.

Krantz MJ, Martin J, et al. QTc Interval Screening in Methadone Treatment. *Ann Intern Med*. 2009 Jan 19. [Epub ahead print] Recommendation 1 (Disclosure): Clinicians should inform patients of arrhythmia risk when they prescribe methadone. Recommendation 2 (Clinical History): Clinicians should ask patients about any history of structural heart disease, arrhythmia, and syncope. Recommendation 3 (Screening): Obtain a pretreatment electrocardiogram for all patients to measure the QTc interval and a follow-up electrocardiogram within 30 days and annually. Additional electrocardiography is recommended if the methadone dosage exceeds 100 mg/d or if patients have unexplained syncope or seizures. Recommendation 4 (Risk Stratification): If the QTc interval is greater than 450 ms but less than 500 ms, discuss the potential risks and benefits with patients and monitor them more frequently. If the QTc interval exceeds 500 ms, consider discontinuing or reducing the methadone dose; eliminating contributing factors, such as drugs that promote hypokalemia; or using an alternative therapy. Recommendation 5 (Drug Interactions): Clinicians should be aware of interactions between methadone and other drugs that possess QT interval-prolonging properties or slow the elimination of methadone.

Leitch A, McGinness P, Wallbridge D. Calculate the QT interval in patients taking drugs for dementia. *BMJ*. 2007 Sep 15;335(7619):557.

Loghin C, Haber H, Beasley CM, et al. Effects of Atomoxetine on the QT Interval in Healthy CYP2D6 Poor Metabolizers. *Br J Clin Pharmacol*. 2012 Jul 16.

Maluli HA, Meshkov AB. A short story of the short QT syndrome. *Cleve Clin J Med*. 2013 Jan;80(1):41-7.

Medical Letter –Treatment Guidelines: Drugs for Cardiac Arrhythmias. June 2007.

MHRA Dec/11 Citalopram and escitalopram are associated with dose-dependent QT interval prolongation and should not be used in those with: congenital long QT syndrome; known pre-existing QT interval prolongation; or in combination with other medicines that prolong the QT interval. ECG measurements should be considered for patients with cardiac disease, and electrolyte disturbances should be corrected before starting treatment. For citalopram, new restrictions on the maximum daily doses now apply: 40 mg for adults; 20 mg for patients older than 65 years; and 20 mg for those with hepatic impairment. For escitalopram, the maximum daily dose for patients older than 65 years is now reduced to 10 mg/day; other doses remain unchanged.

Miceli JJ, Tensfeldt TG, Shiovitz T, et al. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder. *Pharmacotherapy*. 2010 Feb;30(2):127-35.

Mitchell JL, Cuneo BF, , et al. Fetal Heart Rate Predictors of Long QT Syndrome. *Circulation*. 2012 Dec 4;126(23):2688-95.

Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. *Circulation*. 2000 Feb 15;101(6):616-23.

Moretti A, Bellin M, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. *N Engl J Med* 2010. Morganroth J, et al; CAPRIE Study Group. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. *Chest*. 2005 Nov;128(5):3398-406.

Morita H, Wu J, Zipes DP. The QT syndromes: long and short. *Lancet*. 2008 Aug 30;372(9640):750-63.

Napolitano C, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. *JAMA*. 2005 Dec 21;294(23):2975-80.

Nelson S, Leung JG. Torsades de pointes after administration of low-dose aripiprazole. *Ann Pharmacother*. 2013 Feb;47(2):e11.

Newton-Cheh C, Eijgelsheim M, Rice KM, et al. common variants at ten loci influence QT interval duration in the QTGEN Study. *Nature Genetics* 2009; DOI:10.1038/ng.364.

Newton-Cheh Christopher, Lin Angela E., Baggish Aaron L., et al. Case 11-2011 — A 47-Year-Old Man with Systemic Lupus Erythematosus and Heart Failure. *N Engl J Med* 2011; 364:1450-1460. (Infiltrative cardiomyopathy & possible long-QT syndrome due to hydroxychloroquine)

Nuttall GA, Eckerman KM, Jacob KA, et al. Does Low-dose Droperidol Administration Increase the Risk of Drug-induced QT Prolongation and Torsade de Pointes in the General Surgical Population? *Anesthesiology*. 2007 Oct;107(4):531-536. This indicates that the Food and Drug Administration black box warning for low dose droperidol is excessive and unnecessary.

Petropoulou E, Jamshidi Y, Behr ER. The genetics of pro-arrhythmic adverse drug reactions. *Br J Clin Pharmacol*. 2013 Jul 9.

Phillips Mark; Sullivan B; Snyder B; et al. Effect of Enzyte on QT and QTc Intervals. *Arch Intern Med*. 010;170(15):1402-1404.

Rao GA, Mann JR, Shoabi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. *Ann Fam Med* 2014; 12: 121-127.

Roden DM. Clinical practice. Long-QT syndrome. *N Engl J Med*. 2008 Jan 10;358(2):169-76.

Sauer AJ, Newton-Cheh C. Clinical and genetic determinants of torsade de pointes risk. *Circulation*. 2012 Apr 3;125(13):1684-94.

Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. *Circulation*. 2004 Apr 20;109(15):1826-33. Epub 2004 Mar 29.

Schwartz PJ, Spazzolini C, Priori SG, et al. Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. *Circulation*. 2010 Sep 28;122(13):1272-82.

Shah RR. Drug-Induced QT Interval Prolongation: Does ethnicity of the thorough QT study population matter? *Br J Clin Pharmacol*. 2012 Aug 7.

Siddique SM, Shariff N, Vesuwala N, et al. Metoclopramide as a possible cause of prolonged QT syndrome and torsade de pointes in a patient with heart failure and renal insufficiency. *Ann Intern Med*. 2009 Apr 7;150(7):502-4.

Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. *Drugs Aging* 27 (3): 193-209, 2010.

Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. *Int Clin Psychopharmacol*. 2005 Sep;20(5):243-51.

Sugiyama A, Nakamura Y, Nishimura S, et al. Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects. *Br J Clin Pharmacol* 2012; 73: 455–9.

Sy RW, van der Werf C, Chatta IS, et al. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. *Circulation*. 2011;124:2187–2194.

Takaya T, Okamoto M, et al. Torsades de Pointes with QT prolongation related to donepezil use. *J Cardiol*. 2009 Dec;54(3):507-11.

- Taubel J, Naseem A, Wang D, et al. Repeated suprathreshold dosing of strontium ranelate 4g/d over 15 days does not prolong QTc interval in healthy volunteers. *Br J Clin Pharmacol*. 2012 Jan 29.
- Taubel J, Lorch U, Ferber G, et al. Insulin at normal physiological levels does not prolong QTc interval in thorough QT studies performed in healthy volunteers. *Br J Clin Pharmacol*. 2012 Jul 10.
- Thottathil P, Acharya J, Moss AJ, et al. International Long QT Syndrome Investigative Group. Risk of cardiac events in patients with asthma and long-QT syndrome treated with beta(2) agonists. *Am J Cardiol*. 2008 Oct 1;102(7):871-4. Epub 2008 Jul 17.
- Tisdale JE, Jaynes HA, Kingery JR, et al. Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients. *Circ Cardiovasc Qual Outcomes*. 2013 May 28.
- Tsujimoto T, Yamamoto-Honda R, Kajio H, et al. Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients. *Diabetes Care* 2013.
- Vallecillo G et al. Risk of QTc prolongation in a cohort of opioid-dependent HIV-infected patients on methadone maintenance therapy. *Clin Infect Dis* 2013 Aug 14.
- Van Dorn CS et al. QTc Values Among Children and Adolescents Presenting to the Emergency Department. *Pediatrics*. 2011 Dec;128(6):e1395-401.
- van Gorp F, Whyte IM, et al. Clinical and ECG effects of escitalopram overdose. *Ann Emerg Med*. 2009 Sep;54(3):404-8.
- van Gorp F, Duffull S, Hackett LP, Isbister GK. Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal. *Br J Clin Pharmacol* 2012; 73: 402–10.
- Victor M, Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant (citalopram, escitalopram, amitriptyline) use: A cross sectional study of electronic health records. *BMJ* 2013.
- Viskin S, Postema PG, Bhuiyan ZA, et al. The response of the QT interval to the brief tachycardia provoked by standing. A bedside test for diagnosing long-QT syndrome. *J Am Coll Cardiol* 2010
- Vrtovec B, Knezevic I, Poglajen G, et al. Relation of B-Type Natriuretic Peptide Level in Heart Failure to Sudden Cardiac Death in Patients With and Without QT Interval Prolongation. *Am J Cardiol*. 2012 Dec 27.
- Wang NC, Maggioni AP, Konstam MA, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Clinical implications of QRS duration in patients hospitalized with worsening heart failure & reduced left ventricular ejection fraction. *JAMA*. 2008 Jun 11;299(22):2656-66. A prolonged QRS duration appears common in patients with reduced LVEF who are hospitalized for heart failure and is an independent predictor of high postdischarge morbidity and mortality.
- Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-Interval Effects of Methadone, Levomethadyl, and Buprenorphine in a Randomized Trial. *Arch Intern Med*. 2007 Dec 10;167(22):2469-75. Buprenorphine is associated with less QTc prolongation than levomethadyl or methadone and may be a safe alternative.
- Weinberg G, Di Gregorio G, Hiller D, et al. Reversal of haloperidol-induced cardiac arrest by using lipid emulsion. *Ann Intern Med*. 2009 May 19;150(10):737-8.
- Zeuli JD, Wilson JW, Estes LL. Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients. *Antimicrob Agents Chemother*. 2013 Mar;57(3):1121-7.
- Zhang Y, Post WS, Dalal D, et al.. QT-interval duration and mortality: results from the Third National Health and Nutrition Examination Survey. *Arch Intern Med*. 2011;171(19):1727-1733.

CARDIOLOGY

Stable Ischemic Heart Disease

1. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. **STOPP/START** criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing*. 2015 Mar;44(2):213-8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16. PubMed PMID: 25324330; PubMed Central PMCID: PMC4339726.
2. By the American Geriatrics Society 2015 **Beers** Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2015 Oct 8. doi: 10.1111/jgs.13702. [Epub ahead of print] PubMed PMID: 26446832.
3. PL Detail-Document, *Potentially Harmful Drugs in the Elderly: Beers List*. Pharmacist's Letter/Prescriber's Letter. June 2012.
4. PL Detail-Document, *STARTing and STOPping Medications in the Elderly*. Pharmacist's Letter/Prescriber's Letter. September 2011.
5. RxFiles *URINARY INCONTINENCE: Drug Comparison Chart*. RxFiles Drug Comparison Chart. Accessed 16 December 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/Cht-urinary-incontinence.pdf>
6. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Physicians; American Association for Thoracic Surgery; Preventive Cardiovascular Nurses Association; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2012 Dec 18;60(24):e44-e164. doi: 10.1016/j.jacc.2012.07.013. Epub 2012 Nov 19.
7. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabat M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirim A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J*. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/eh296. Epub 2013 Aug 30.
8. Appel LJ, Espeland MA, Easter L, et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). *Arch Intern Med*. 2001;161:685-93
9. Management of Patients With Stable Ischemic Heart Disease: Executive Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons
10. Stable Ischemic Heart Disease. *Annals of Internal Medicine*, 2014 (January 7): ITC1-1 – ITC1-16.
11. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Physicians;

American Association for Thoracic Surgery; Preventive Cardiovascular Nurses Association; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2012 Dec 18;60(24):e44-e164. doi: 10.1016/j.jacc.2012.07.013. Epub 2012 Nov 19.

12. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabat M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirim A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J*. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/eh296. Epub 2013 Aug 30.
13. Lexi-Comp, Inc. (Lexi-Drugs™). Lexi-Comp, Inc.; February 27, 2014.
14. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med* 2007;356:1503–16. [PubMed: 17387127]
15. The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* 2009;360:2503–2515. [PubMed: 19502645]
16. De Bruyne B, Pijls NH, Kalesan B, et al. FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. *N Engl J Med*. 2012 Sep 13;367(11):991-1001. doi: 10.1056/NEJMoa1205361. Epub 2012 Aug 27.
17. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? *Lancet*. 2004 Nov 6;364(9446):1684-9.
18. Weiss, B. Diagnostic Evaluation of Urinary Incontinence in Geriatric Patients. *Am Fam Physician*. 1998 Jun 1;57(11):2675-2684.
19. Lanier JB, Mote MB, Clay EC. *Evaluation and management of orthostatic hypotension*. *Am Fam Physician*. 2011 Sep 1;84(5):527-36.

ENDOCRINE & METABOLIC

Diabetes

1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee of the Canadian Diabetes Advisory Board. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. *Can J Diabetes* 2013;37(suppl 1):S1–212.
2. Allen M, Kelly K, Fleming K. Uncertainty about the systolic blood pressure target in people with diabetes. *Can Fam Physician*. 2013 Feb;59(2):128-31.
3. ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. *N Engl J Med*. 2010 Mar 18. Supplement App: http://www.nejm.org/doi/suppl/10.1056/NEJMoa1001282/suppl_file/nejm_accord_1563sa1.pdf
4. D.L. Bhatt S.P. Marso A.T. Hirsch Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus *Am J Cardiol* 90 2002 625 628
5. F.A. McAlister Renin Angiotensin System Modulator Meta-Analysis Investigators Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials *Eur Heart J* 33 2012 505514
6. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. *Kidney Int*. 1998 Oct;54(4):1283-9.
7. ACCF/AHA 2011 Expert Consensus on Hypertension in the Elderly
8. Rosendorff C, Black HR, Cannon CP, et al; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. *Circulation*. 2007 May 29;115(21):2761-88.
9. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. *BMJ*. 2011 Jul 26;343:d4169. doi: 10.1136/bmj.d4169. Review. PubMed PMID: 21791495; PubMed Central PMCID: PMC3144314.
10. Flory JH, Hennessy S. Metformin use reduction in mild to moderate renal impairment: possible inappropriate curbing of use based on food and drug administration contraindications. *JAMA Intern Med*. 2015 Mar;175(3):458-9. doi: 10.1001/jamainternmed.2014.6936. PubMed PMID: 25561419.
11. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: *N Engl J Med*. 2015 Aug 6;373(6):586. PubMed PMID: 26052984.
12. Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2013 Oct 26;382(9902):1413-23. doi: 10.1016/S0140-6736(13)61500-7. Epub 2013 Aug 13. PubMed PMID: 23948125.
13. Geller AI, Shehab N, Lovegrove MC, Kegler SR, Weidenbach KN, Ryan GJ, Budnitz DS. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. *JAMA Intern Med*. 2014 May;174(5):678-86. doi: 10.1001/jamainternmed.2014.136. PubMed PMID: 24615164.

GASTROINTESTINAL

Acid Suppression

1. CADTH - COMPUS Scientific Report: Evidence for PPI in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease [Scientific Report], March 2007. Accessible online at: http://www.cadth.ca/media/compus/reports/compus_Scientific_Report_final.pdf {Related COMPUS reports/tools available at: <http://www.cadth.ca/index.php/en/compus/current-topics/ppis>}
2. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD003244.:CD003244.

GASTROINTESTINAL

Constipation

1. By the American Geriatrics Society 2015 **Beers** Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2015 Oct 8. doi: 10.1111/jgs.13702. [Epub ahead of print] PubMed PMID: 26446832.
2. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. **STOPP/START** criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing*. 2015 Mar;44(2):213-8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16. PubMed PMID: 25324330; PubMed Central PMCID: PMC4339726.
3. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. **STOPP/START** criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing*. 2015 Mar;44(2):213-8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16. PubMed PMID: 25324330; PubMed Central PMCID: PMC4339726.
4. Ford AC, Moayyedi P, Lacy BE, et al; Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. *Am J Gastroenterol*. 2014 Aug;109 Suppl 1:S2-26.
5. American Gastroenterological Association, Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. *Gastroenterology*. 2013 Jan;144(1):211-7.
6. Bharucha AE, Pemberton JH, Locke GR 3rd. American Gastroenterological Association technical review on constipation. *Gastroenterology*. 2013 Jan;144(1):218-38.
7. Gray JR. What is chronic constipation? Definition and diagnosis. *Can J Gastroenterol*. 2011 Oct;25 Suppl B:7B-10B.
8. Andrews CN, Storr M. The pathophysiology of chronic constipation. *Can J Gastroenterol*. 2011 Oct;25 Suppl B:16B-21B.
9. Jamshed N, Lee ZE, Olden KW. Diagnostic approach to chronic constipation in adults. *Am Fam Physician*. 2011 Aug 1;84(3):299-306.
10. Pare P. The approach to diagnosis and treatment of chronic constipation: suggestions for a general practitioner. *Can J Gastroenterol*. 2011 Oct 25; 25 Suppl B: 36B-40B.
11. Liu LW. Chronic constipation: current treatment options. *Can J Gastroenterol*. 2011 Oct;25 Suppl B:22B-28B.
12. Paré P, Bridges R, Champion MC, Ganguli SC, Gray JR, Irvine EJ, Plourde V, Poitras P, Turnbull GK, Moayyedi P, Flook N, Collins SM. Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment. *Can J Gastroenterol*. 2007 Apr;21 Suppl B:3B-22B.
13. Kosar L, Schuster B. RxFiles. Management of Constipation. October 2014.
14. Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response Report: Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation: A Review of the Clinical Effectiveness. June 2014.
15. Fleming V, Wade WE. A review of laxative therapies for treatment of chronic constipation in older adults. *Am J Geriatr Pharmacother*. 2010 Dec; 8(6):514-50.
16. Gallegos-Orozco JF, Foxx-Orenstein AE, Sterler SM, Stoa JM. Chronic constipation in the elderly. *Am J Gastroenterol*. 2012 Jan;107(1):18-25.
17. Gandell D, Straus SE, Bundookwala M et al. Treatment of constipation in older people. *CMAJ*. 2013 May 14;185(8):663-70.
18. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. *Scand J Gastroenterol*. 1997 Sep;32(9):920-4. (**Bristol Stool Chart**)
19. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. *Aliment Pharmacol Ther*. 2007 Mar 1;25(5):599-608.
20. Branch RL, Butt T. Adverse Drug Reaction Bulletin: Drug-induced constipation. August 2009.
21. Robson KM, Kiely DK, Lembo T. Development of constipation in nursing home residents. *Dis Colon Rectum*. 2000 Jul; 43(7): 940-3.
22. Lindeman RD, Romero LJ, Liang HC, Baumgartner RN, Koehler KM, Garry PJ. Do elderly persons need to be encouraged to drink more fluids? *J Gerontol A Biol Sci Med Sci*. 2000 Jul; 55(7):M361-6.

23. Lever E, Cole J, Scott SM, Emery PW, Whelan K. Systematic review: the effect of prunes on gastrointestinal function. *Aliment Pharmacol Ther.* 2014 Oct; 40(7): 750-8.
24. Attaluri A, Donahoe R, Valestin J, Brown K, Rao SS. Randomized clinical trial: dried plumes (prunes) versus psyllium for constipation. *Aliment Pharmacol Ther.* 2011 Apr; 33(7): 822-8.

GENITOURINARY

Renal Insufficiency

1. Lam EI, Webb MC, Simpson De, et al. Estimate of glomerular filtration rate in older patients with renal insufficiency: is the modification of diet in renal disease formula an improvement? *J Am Geriatr Soc.* 2003; 51:1012-7.
2. Carter JL, Stevens PE, Irving JE, Lamb EJ. Estimating glomerular filtration rate: comparison of the CKD-EPI and MDRD equations in a large UK cohort with particular emphasis on the effect of age. *QJM.* 2011 Oct;104(10):839-47. doi: 10.1093/qjmed/hcr077. Epub 2011 Jun 6. PubMed PMID: 21652537.
3. Arora P, Vasa P, Brenner D, et al. Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. *CMAJ* 2013. DOI:10.1503/cmaj.120833.
4. McClellan WM, Resnick B, Lei L, et al. Prevalence and severity of chronic kidney disease and anemia in the nursing home population. *J Am Med Dir Assoc* 2010 Jan; 11(1): 33-41.
5. Sanjeevkumar RP, Wiggins JE. *Kidney Diseases and Disorders.* Chapter 52. *Geriatrics Care Online.*
6. Richardson MM. Precision versus Approximation: The Trade Off in Assessing Kidney Function and Drug Dosing. *Pharmacotherapy* 2010; 30(8): 758-761.
7. Nguyen MT, Maynard SE, Kimmel PL. Misapplications of Commonly Used Kidney Equations: Renal Physiology in Practice. *Clin J Am Soc Nephrol* 2009; 4: 528-534.
8. *The Kidneys (Chapter 7). Basic Skills in Interpreting Laboratory Data.* Edited by Mary Lee. 4th Edition. 2009. American Society of Health Systems Pharmacists.
9. O'Riordan P, Stevens PE, Lamb EJ. Estimated glomerular filtration rate. *BMJ.* 2014 Jan 24;348:g264. doi: 10.1136/bmj.g264. Review. PubMed PMID: 24464281.
10. Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. *Clin J Am Soc Nephrol.* 2010 Jun;5(6):1003-9. doi: 10.2215/CJN.06870909. Epub 2010 Mar 18. PubMed PMID: 20299365; PubMed Central PMCID: PMC2879308.
11. Saskatchewan Drug Information Service (SDIS). *Drug Dosage Adjustment in Chronic Kidney Disease: The Pharmacist's Role.* Nov 2012;29(3)
12. Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. *Clin J Am Soc Nephrol.* 2010 Jun;5(6):1003-9. doi: 10.2215/CJN.06870909. Epub 2010 Mar 18. PubMed PMID: 20299365; PubMed Central PMCID: PMC2879308.
13. Chen Y-C, et al. Risk factors associated with adverse drug events among older adults in emergency department. *Eur J Intern Med* (2013), <http://dx.doi.org/10.1016/j.ejim.2013.10.006>
14. Hellden A, Bergman U, von Euler M, et al. Adverse drug reactions and impaired renal function in elderly patients admitted to the emergency department: a retrospective study. *Drugs Aging* 2009; 26(7): 595-606.
15. Hu KT, Matayoshi A, Stevenson FT. Calculation of the estimated creatinine clearance in avoiding drug dosing errors in the older patient. *Am J Med Sci* 2001;322:133-136
16. Saskatchewan Drug Information Service (SDIS). *Drug Dosage Adjustment in Chronic Kidney Disease: The Pharmacist's Role.* Nov 2012;29(3)
17. Pretorius RW, Gataric G, Swedlund S, et al. Reducing the Risk of Adverse Drug Events in Older Adults. *Am Fam Physician* 2013; Mar 1; 87(5): 331-336.

GENITOURINARY

Urinary Incontinence

1. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. **STOPP/START** criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing*. 2015 Mar;44(2):213-8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16. PubMed PMID: 25324330; PubMed Central PMCID: PMC4339726.
2. By the American Geriatrics Society 2015 **Beers** Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2015 Oct 8. doi: 10.1111/jgs.13702. [Epub ahead of print] PubMed PMID: 26446832.
3. PL Detail-Document, *Potentially Harmful Drugs in the Elderly: Beers List*. Pharmacist's Letter/Prescriber's Letter. June 2012.
4. PL Detail-Document, *STARTing and STOPping Medications in the Elderly*. Pharmacist's Letter/Prescriber's Letter. September 2011.
5. RxFiles *URINARY INCONTINENCE: Drug Comparison Chart*. RxFiles Drug Comparison Chart. Accessed 16 December 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/Cht-urinary-incontinence.pdf>
6. Bettez M, Tu LM, Carlson K, Corcos J, Gajewski J, Jolivet M, Bailly G. 2012 Update: Guidelines for Adult Urinary Incontinence Collaborative Consensus Document for the **Canadian Urological Association**. *Can Urol Assoc J* 2012;6(5):354-63. <http://dx.doi.org/10.5489/cuaj.12248>
7. Society of Obstetricians and Gynaecologists of Canada (**SOGC**). SOGC clinical practice guidelines: treatments for **overactive bladder**: focus on pharmacotherapy. *J Obstet Gynaecol Can* 2012 Nov;34(11):1092-101.
8. Gormley EA, Lightner DJ, Burgio KL, Chai TC, et al. Diagnosis and treatment of **overactive bladder** (non-neurogenic) in adults: **AUA/SUFU guideline**. Linthicum (MD): American Urological Association (AUA); **2012** May. (*J Urol*. 2012 Oct 19. pii: S0022-5347(12)04959-2.)
9. Urinary Incontinence in Women: NICE Guidelines. <http://www.nice.org.uk/nicemedia/live/14271/65143/65143.pdf> National Institute for Health and Clinical Excellence (**NICE**) clinical guideline 171; September 2013
10. The Canadian continence foundation. Incontinence: A Canadian perspective; 2007. http://www.canadiancontinence.ca/pdf/Research_paper_August2007.pdf (Accessed 18 December 2013)
11. Offermans MP, Du Moulin MF, Hamers JP, et al. Prevalence of urinary incontinence and associated risk factors in nursing home residents: a systematic review. *Neurourol Urodyn* 2009;28:288-94.
12. Durso SC, Sullivan GM, eds. *Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine*. 8th ed. New York: American Geriatrics Society; 2013
13. Ouslander JG. Management of Overactive Bladder. *NEJM* 2004;350:786-99.
14. Diokno A, Sand P, Labasky R, et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. *Int Urol Nephrol*. 2002;34(1):43-9.
15. Brown JS, Vittinghoff E, Wyman JF, Stone KL, Nevitt MC, Ensrud KE, Grady D. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. *J Am Geriatr Soc*. 2000 Jul;48(7):721-5.
16. Bogner HR, Gallo JJ, Sammel MD, Ford DE, Armenian HK, Eaton WW. Urinary incontinence and psychological distress in community-dwelling older adults. *J Am Geriatr Soc*. 2002 Mar;50(3):489-95.
17. RxFiles *URINARY INCONTINENCE: Drug Comparison Chart*. RxFiles Drug Comparison Chart. Accessed 16 December 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/Cht-urinary-incontinence.pdf>
18. Dmochowski RR, Sanders SW, Appell RA, Nitti VW, Davila GW. Bladder-health diaries: an assessment of 3-day vs 7-day entries. *BJU Int*. 2005 Nov;96(7):1049-54.
19. Hersh L, Salzman B. Clinical management of urinary incontinence in women. *Am Fam Physician*. 2013 May 1;87(9):634-40.
20. Urinary Incontinence: The management of urinary incontinence in women. www.nice.org.uk/nicemedia/pdf/CG40fullguideline.pdf National Institute for Health and Clinical Excellence (**NICE**) clinical guideline 40; October 2006:1-14.

21. Urinary Incontinence: The management of urinary incontinence in women. www.nice.org.uk/nicemedia/pdf/CG40fullguideline.pdf National Institute for Health and Clinical Excellence (NICE) clinical guideline 40; October 2006:1-14.
22. Urinary Incontinence: The management of urinary incontinence in women. www.nice.org.uk/nicemedia/pdf/CG40fullguideline.pdf National Institute for Health and Clinical Excellence (NICE) clinical guideline 40; October 2006:1-14.
23. Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int. 2008 Jul;102(1):62-6.
24. **(Physiotherapy-** especially if pt can't isolate or exercising wrong muscles, or if stops breathing during Kegels; Saskatoon Health Region: **Pelvic Floor Rehab Program** 655-8208, typically sees females q1-2weeks x 8 times, waiting list ~6months; **Private Clinics** in Saskatoon also treat, quicker access, 3rd party coverage?: Bourassa & Daniels Kimber) **Nurse Continence Advisor:** Eliza Meggs RN,NCA (Nightingale Nursing Group) Phone: 306-652-3314
25. Urinary Incontinence: The management of urinary incontinence in women. www.nice.org.uk/nicemedia/pdf/CG40fullguideline.pdf National Institute for Health and Clinical Excellence (NICE) clinical guideline 40; October 2006:1-14.
26. Dumoulin C, Hay-Smith J. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD005654. DOI:10.1002/14651858.CD005654.pub2.
27. Urinary Incontinence: The management of urinary incontinence in women. www.nice.org.uk/nicemedia/pdf/CG40fullguideline.pdf National Institute for Health and Clinical Excellence (NICE) clinical guideline 40; October 2006:1-14.
28. Diokno A, Sand P, Labasky R, et al. Long - term safety of extended - release oxybutynin chloride in a community - dwelling population of participants with overactive bladder: a one - year study. Int Urol Nephrol. 2002;34(1):43-9.
29. Durso SC, Sullivan GM, eds. Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine. 8th ed. New York: American Geriatrics Society; 2013.
30. Incontinence in Women: NICE Guidelines. <http://www.nice.org.uk/nicemedia/live/14271/65143/65143.pdf> National Institute for Health and Clinical Excellence (NICE) clinical guideline 171; September 2013.
31. Herbison GP, Dean N. Weighted vaginal cones for urinary incontinence. Cochrane Database Syst Rev. 2013 Jul 8; 7:CD002114. doi: 10.1002/14651858.CD002114.pub2. Review. PubMed PMID: 23836411.
32. Wang Y, Zhishun L, Peng W, Zhao J, Liu B. Acupuncture for stress urinary incontinence in adults. Cochrane Database Syst Rev. 2013 Jul 1; 7:CD009408. doi: 10.1002/14651858.CD009408.pub2. Review. PubMed PMID: 23818069.
33. Urinary Incontinence: The management of urinary incontinence in women. www.nice.org.uk/nicemedia/pdf/CG40fullguideline.pdf National Institute for Health and Clinical Excellence (NICE) clinical guideline 40; October 2006:1-14.
34. Bettez M, Tu LM, Carlson K, Corcos J, Gajewski J, Jolivet M, Bailly G. 2012 Update: Guidelines for Adult Urinary Incontinence Collaborative Consensus Document for the Canadian Urological Association. Can Urol Assoc J 2012;6(5):354-63. <http://dx.doi.org/10.5489/cuaj.12248>.
35. Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD003193. DOI: 10.1002/14651858.CD003193.pub4.
36. Moga DC, Carnahan RM, Lund BC, Pendergast JF, Wallace RB, Torner JC, Li Y, Chrischilles EA. Risks and benefits of bladder antimuscarinics among elderly residents of Veterans Affairs Community Living Centers. J Am Med Dir Assoc. 2013 Oct; 14(10):749-60. doi: 10.1016/j.jamda.2013.03.008.
37. Nabi G, Cody JD, Ellis G, Herbison P, Hay - Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006 Oct 18; (4):CD003781.
38. Robinson D, Cardozo L. Antimuscarinic drugs to treat overactive bladder. BMJ. 2012 Mar 27; 344:e2130.
39. Madhuvrata P,Cody JD, EllisG,HerbisonGP,Hay-Smith EJC.Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD005429. DOI: 10.1002/14651858.CD005429.pub2.
40. Siegler, EL et al. Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin Pharmacol Ther 2004; 75:484-8.

41. Edwards, KR et al. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. Editorial Letter. JAGS 2002;50:1165-1166.
42. Donnellan, CA et al. Oxybutynin and cognitive dysfunction. BMJ 1997; 315:1363-1364.
43. Kay G, Crook T, Rebeda L, Lima R, Ebinger U, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. EurUrol 2006; 50(2):317-26.
44. RxFiles URINARY INCONTINENCE: Drug Comparison Chart. RxFiles Drug Comparison Chart. Accessed 16 December 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/Cht-urinary-incontinence.pdf>
45. Siegler, EL et al. Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin Pharmacol Ther 2004; 75:484-8.
46. Edwards, KR et al. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. Editorial Letter. JAGS 2002; 50:1165-1166.
47. Donnellan, CA et al. Oxybutynin and cognitive dysfunction. BMJ 1997; 315:1363-1364.
48. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a B3-adrenoreceptor agonist, in patients with overactive bladder: results from a randomised European–Australian phase 3 trial. Eur Urol. 2013; 63(2):283–95.
49. Sanford M. Mirabegron: a review of its use in patients with overactive bladder syndrome. Drugs. 2013 Jul; 73(11):1213-25. doi: 10.1007/s40265-013-0086-3. Review. PubMed PMID: 23818156.
50. Haueusler G et al. Drug therapy of urinary urge incontinence: A systematic review. Obstet Gynecol 2002; 100:1003-16.
51. Scottish Intercollegiate Guidelines Network. Management of urinary incontinence in primary care. 2004; December. www.sign.ac.uk/pdf/sign79.pdf
52. Edwards, KR et al. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. Editorial Letter. JAGS 2002; 50:1165 - 1166.
53. Steers WD, Herschorn S, Kreder KJ, et al. Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int. 2007 Aug; 100(2):337-45. Epub 2007 May 19.
54. Ghoniem GM, Van Leeuwen JS, et al. Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol. 2005 May; 173(5):1647 - 53.
55. van Kerrebroeck P, Abrams P, Lange R, et al. Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG. 2004 Mar;111(3):249-57.
56. Millard RJ, Moore K, Rencken R, et al. Duloxetine UI Study Group. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four - continent randomized clinical trial. BJU Int. 2004 Feb; 93(3):311-8.
57. Norton PA, Zinner NR, Yalcin I, Bump RC; Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol. 2002 Jul; 187(1):40-8.
58. Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol. 2003 Oct; 170(4 Pt 1):1259-63.
59. Kim S, Liu S, Tse V. Management of Urinary Incontinence in Adults. Aust Prescriber. 2014; 34:10-3
60. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'dow J, Nordling J, de la Rosette JJ; European Association of Urology. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013 Jul; 64(1):118-40. doi:10.1016/j.eururo.2013.03.004.

61. American Urological Association Education and Research, Inc. Guideline on the management of benign prostatic hyperplasia (BPH). Linthicum (MD): American Urological Association Education and Research, Inc.; 2010. 34 p. Gravas S, Bachmann A, Descazeaud A, et al. Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), including benign prostatic obstruction (BPO). Arnhem (The Netherlands): European Association of Urology (EAU); 2014 Apr.
62. Burgio KL, Goode PS, Johnson TM, Hammontree L, Ouslander JG, Markland AD, Colli J, Vaughan CP, Redden DT. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. *J Am Geriatr Soc*. 2011 Dec; 59(12):2209-16.
63. Wilt TJ, Mac Donald R, Rutks I. Tamsulosin for benign prostatic hyperplasia. *Cochrane Database Syst Rev*. 2003; (1):CD002081.
64. Norman, Richard W. *Genitourinary Disorders: Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia*. Ed. Jean Gray. 6th ed. Ottawa: Canadian Pharmacists Association, 2011. Accessed 9 Aug 2012 at <http://www.e-therapeutics.ca/tc.showChapter.action?documentId=c0050#c0050n00017>.
65. Roehrborn CG et al. Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. *J Urol* 2014 Apr; 191:1045.
66. Miller MS. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms. *Ann Pharmacother*. 2013 Feb; 47(2):278-83. doi: 10.1345/aph.1R528. Epub 2013 Feb 5. Review. PubMed PMID: 23386068.
67. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. *N Engl J Med* 2003; 349:2387-98.
68. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. *Eur Urol*. 2010 Jan; 57(1):123-31. doi: 10.1016/j.eururo.2009.09.035. Epub 2009 Sep 19. Erratum in: *Eur Urol*. 2010 Nov;58(5):801. PubMed PMID: 19825505
69. Fullhase C, Chapple C, Cornu JN, et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. *Eur Urol*. 2013 Aug;64(2):228-43
70. Tracklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. *Cochrane Database Syst Rev*. 2012 Dec 12; 12:CD001423. doi: 10.1002/14651858.CD001423.pub3.
71. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster HE Jr, Kaplan SA, McCullough A, Andriole GL, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, McVary KT; Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study Group. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. *JAMA*. 2011 Sep 28;306(12):1344-51. doi: 10.1001/jama.2011.1364.
72. RxFiles URINARY INCONTINENCE: Drug Comparison Chart. RxFiles Drug Comparison Chart. Accessed 16 December 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/Cht-urinary-incontinence.pdf>

Additional references:

- Abrams P, Kelleher C, Staskin D, et al. Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony). *Eur Urol*. 2014 Feb 19.
- Casabé A, Roehrborn CG, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. *J Urol*. 2014 Mar.
- Elterman DS, Kaplan SA. Lower urinary tract symptoms in a 66-year-old man. *CMAJ*. 2014 Apr 15;186(7):525-7.
- Gravas S, Bachmann A, Descazeaud A, et al. Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), including benign prostatic obstruction (BPO). Arnhem (The Netherlands): European Association of Urology (EAU); 2014 Apr.
- Hollingsworth JM, Wilt TJ. Lower urinary tract symptoms in men. *BMJ*. 2014 Aug 14;349:g4474.
- Kim S, Liu S, Tse V. Management of urinary incontinence in adults. *Australian Prescriber* 37.1. 2014.
- Myers DL. Female Mixed Urinary Incontinence-A Clinical Review. *JAMA*. 2014;311(19):2007-2014. doi:10.1001/jama.2014.4299
- Rees J, Bultitude M, Challacombe B. The management of lower urinary tract symptoms in men. *BMJ*. 2014 Jun 24;348:g3861.

GENITOURINARY

Urinary Tract Infections

1. Colgan R, Nicolle LE, McGlone A, Hooton TM. Asymptomatic Bacteriuria in Adults. *Am Fam Physician*. 2006 Sep; 15;74(6):985-990.
2. Trautner BW, Darouiche RO. Role of biofilm in catheter-associated urinary tract infection. *Am J Infect Control*. 2004 May;32(3):177-83. Review. PubMed PMID: 15153930; PubMed Central PMCID: PMC2963581.
3. Trautner BW, Darouiche RO. Role of biofilm in catheter-associated urinary tract infection. *Am J Infect Control*. 2004 May;32(3):177-83. Review. PubMed PMID: 15153930; PubMed Central PMCID: PMC2963581.
4. Anti-infective Review Panel. **Anti-infective guidelines for community-acquired infections**. Toronto: MUMS Guideline Clearinghouse; 2012
5. Blondel-Hill E, Fryters S. **Bugs & Drugs: An antimicrobial/infectious disease reference**. Alberta Health Services, Alberta Health, British Columbia of Health Pharmaceutical Services Division; 2012.
6. Regier L. Urinary Tract Infections: Adult Treatment Options. **RxFiles** 9th edition. Saskatoon SK; 2012.
7. **Saskatchewan Infection Prevention & Control Program**. Guidelines for the Prevention & Treatment of Urinary Tract Infections in Continuing Care Settings. Government of Saskatchewan; April 2013.
8. Gupta K, Hooton TM, Naber KG et al; **Infectious Diseases Society of America**; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis*. 2011 Mar 1;52(5):e103-20.
9. Lutters M, Vogt-Ferrier NB. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. *Cochrane Database Syst Rev*. 2008 Jul 16;(3):CD001535.
10. Vogel T, Verreault R, Gourdeau M et al. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial. *CMAJ*. 2004 Feb 17;170(4):469-73.
11. Matthews SJ, Lancaster JW. Urinary tract infections in the elderly population. *Am J Geriatr Pharmacother*. 2011 Oct;9(5):286-309.
12. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. *Cochrane Database Syst Rev*. 2008 Apr 16;(2):CD005131.
13. Allan M, Nicolle L. Cranberry juice/tablets for the prevention of urinary tract infection: naturally the best? *Tools for Practice*, March 4, 2013.
14. Jepson RG, Williams G, Craig JC. *Cochrane Database Syst Rev*. 2012 Oct 17; 10:CD001321.
15. Wang CH, Fang CC, Chen NC, et al. *Arch Intern Med*. 2012 Jul 9; 172(13):988-96.
16. Allan M, Nicolle L. Cranberry juice/tablets for the prevention of urinary tract infection: naturally the best? *Tools for Practice*, March 4, 2013.
17. Jepson RG, Williams G, Craig JC. *Cochrane Database Syst Rev*. 2012 Oct 17; 10:CD001321.
18. Wang CH, Fang CC, Chen NC, et al. *Arch Intern Med*. 2012 Jul 9; 172(13):988-96.
19. Wang CH, Fang CC, Chen NC, et al. *Arch Intern Med*. 2012 Jul 9; 172(13):988-96.
20. Allan M, Nicolle L. Cranberry juice/tablets for the prevention of urinary tract infection: naturally the best? *Tools for Practice*, March 4, 2013.
21. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. *Cochrane Database Syst Rev*. 2008 Apr 16;(2):CD005131.
22. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. *Cochrane Database Syst Rev*. 2008 Apr 16;(2):CD005131.
23. Grin PM, Kowalewska PM, Alhazzan W, Fox-Robichaud AE. Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis. *Can J Urol*. 2013 Feb;20(1):6607-14. Review. PubMed PMID: 23433130.

24. Singh N, Gandhi S, McArthur E, Moist L, Jain AK, Liu AR, Sood MM, Garg AX. Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. *CMAJ*. 2015 Jun 16;187(9):648-56. doi: 10.1503/cmaj.150067. Epub 2015 Apr 27. PubMed PMID: 25918178; PubMed Central PMCID: PMC4467927.
25. Singh N, Gandhi S, McArthur E, Moist L, Jain AK, Liu AR, Sood MM, Garg AX. Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. *CMAJ*. 2015 Jun 16;187(9):648-56. doi: 10.1503/cmaj.150067. Epub 2015 Apr 27. PubMed PMID: 25918178; PubMed Central PMCID: PMC4467927.
26. Gupta K, Hooton TM, Naber KG et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis*. 2011 Mar 1;52(5):e103-20.
27. Lutters M, Vogt-Ferrier NB. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. *Cochrane Database Syst Rev*. 2008 Jul 16;(3):CD001535.
28. McIsaac W, Moineddin R, Meaney C et al. Antibiotic-resistant *Escherichia coli* in women with acute cystitis in Canada. *Can J Infect Dis Med Microbiol*. Autumn 2013; 24(3):143-149.

Additional References:

- O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. **STOPP/START** criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing*. 2014 Oct 16.
- By the American Geriatrics Society 2015 **Beers** Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2015 Oct 8. doi: 10.1111/jgs.13702. [Epub ahead of print] PubMed PMID: 26446832.
- PL Detail-Document, Potentially Harmful Drugs in the Elderly: Beers List. *Pharmacist's Letter/Prescriber's Letter*. June 2012.
- PL Detail-Document, **STARTing** and **STOPPING** Medications in the Elderly. *Pharmacist's Letter/Prescriber's Letter*. September 2011.
- Toward Optimized Practice**. Guideline for the Diagnosis & Management of Urinary Tract Infections in Long-Term Care. 2010.
- KFL&A Public Health**. Antibiotic Stewardship: Treatment Guidelines for Long-term Care Facilities; December 2012.
- Pharmacists Letter**. Detail-Document: Choosing a UTI Antibiotic for Elderly Patients. December 2011.
- Ferraro G, Ambrosi G, Bucci L et al. Fosfomicin trometamol versus norfloxacin in the treatment of uncomplicated lower urinary tract infections of the elderly. *Chemotherapy*. 1990; 36 Suppl 1:46-9.

MUSCULOSKELETAL & CONNECTIVE TISSUE

Falls

1. Kwan, E, Straus, SE. Assessment and Management of Falls in Older People. *CMAJ*. 2014 Nov; 186(16):610-621.
2. Kendrick D, Kumar A, Carpenter H, Zijlstra GAR, Skelton DA, Cook JR, Stevens Z, Belcher CM, Haworth D, Gawler SJ, Gage H, Masud T, Bowling A, Pearl M, Morris RW, Iliffe S, Delbaere K. Exercise for reducing fear of falling in older people living in the community. *Cochrane Database of Systematic Reviews* 2014, Issue 11. Art. No.: CD009848. DOI: 10.1002/14651858.CD009848.pub2.
3. Panel on Prevention of Falls in Older Persons. Summary of the Updated American Geriatrics Society/British Geriatrics Society Clinical Practice Guideline for Prevention of Falls in Older Persons. *J Am Geriatr Soc*. 2011;59:148-157.
4. American Geriatrics Society. Geriatrics Evaluation and Management Tools: Falls. Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine. New York, NY: 2013.
5. Hill KD, Wee R. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. *Drugs Aging*. 2012 Jan 1;29(1):15-30.doi: 10.2165/11598420-000000000-00000. Review.
6. Kwan, E, Straus, SE. Assessment and Management of Falls in Older People. *CMAJ*. 2014 Nov;186(16):610-621.
7. Panel on Prevention of Falls in Older Persons, American Geriatrics Society and British Geriatrics Society. Summary of the Updated American Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. *J Am Geriatr Soc*. 2011 Jan;59(1):148-57. doi:10.1111/j.1532-5415.2010.03234.x.
8. Drug Information Service. Preventing Falls in the Elderly: What Primary Care Clinicians can do to Reduce Injury and Death. Alosa Foundation. 2014.
9. Panel on Prevention of Falls in Older Persons. Summary of the Updated American Geriatrics Society/British Geriatrics Society Clinical Practice Guideline for Prevention of Falls in Older Persons. *J Am Geriatr Soc*. 2011;59:148-157.
10. American Geriatrics Society. Geriatrics Evaluation and Management Tools: Falls. Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine. New York, NY: 2013.
11. Hartikainen S, Lönnroos E, Louhivuori K. Medication as a risk factor for falls: critical systematic review. *J Gerontol A Biol Sci Med Sci*. 2007 Oct;62(10):1172-81. Review. PubMed PMID: 17921433.
12. Panel on Prevention of Falls in Older Persons. Summary of the Updated American Geriatrics Society/British Geriatrics Society Clinical Practice Guideline for Prevention of Falls in Older Persons. *J Am Geriatr Soc*. 2011;59:148-157.
13. Hill KD, Wee R. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. *Drugs Aging*. 2012 Jan 1;29(1):15-30.doi: 10.2165/11598420-000000000-00000. Review.
14. Panel on Prevention of Falls in Older Persons, American Geriatrics Society and British Geriatrics Society. Summary of the Updated American Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. *J Am Geriatr Soc*. 2011 Jan;59(1):148-57. doi:10.1111/j.1532-5415.2010.03234.x.
15. Cameron ID, Gillespie LD, Robertson MC, Murray GR, Hill KD, Cumming RG, Kerse N. Interventions for preventing falls in older people in care facilities and hospitals. *Cochrane Database of Systematic Reviews* 2012, Issue 12. Art. No.: CD005465. DOI: 10.1002/14651858.CD005465.pub3.
16. Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE. Interventions for preventing falls in older people living in the community. *Cochrane Database of Systematic Reviews* 2012, Issue 9. Art. No.: CD007146. DOI: 10.1002/14651858.CD007146.pub3.
17. Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE. Interventions for preventing falls in older people living in the community. *Cochrane Database of Systematic Reviews* 2012, Issue 9. Art. No.: CD007146. DOI: 10.1002/14651858.CD007146.pub3.
18. Santesso N, Carrasco-Labra A, Brignardello-Petersen R. Hip protectors for preventing hip fractures in older people. *Cochrane Database of Systematic Reviews* 2014, Issue 3. Art. No.: CD001255. DOI: 10.1002/14651858.CD001255.pub5.

19. CADTH. Hip Protectors: A Review of the Comparative Clinical and Cost-Effectiveness. 11 Feb 2015.
20. Panel on Prevention of Falls in Older Persons, American Geriatrics Society and British Geriatrics Society. Summary of the Updated American Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. *J Am Geriatr Soc.* 2011 Jan;59(1):148-57. doi:10.1111/j.1532-5415.2010.03234.x.
21. Fraser LA, Liu K, Naylor KL, Hwang YJ, Dixon SN, Shariff SZ, Garg AX. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. *JAMA Intern Med.* 2015 Mar;175(3):450-2. doi: 10.1001/jamainternmed.2014.6930. PubMed PMID: 25581312.
22. Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE. Interventions for preventing falls in older people living in the community. *Cochrane Database of Systematic Reviews* 2012, Issue 9. Art. No.: CD007146. DOI: 10.1002/14651858.CD007146.pub3.
23. Hill KD, Wee R. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. *Drugs Aging.* 2012 Jan 1;29(1):15-30.doi: 10.2165/11598420-000000000-00000. Review.
24. Hartikainen S, Lönnroos E, Louhivuori K. Medication as a risk factor for falls: critical systematic review. *J Gerontol A Biol Sci Med Sci.* 2007 Oct;62(10):1172-81. Review. PubMed PMID: 17921433.
25. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. *J Am Geriatr Soc.* 2012 Apr;60(4):616-31. doi:10.1111/j.1532-5415.2012.03923.x. Epub 2012 Feb 29. Review.
26. Hill KD, Wee R. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. *Drugs Aging.* 2012 Jan 1;29(1):15-30.doi: 10.2165/11598420-000000000-00000. Review.
27. The 2015 Canadian Hypertension Education Program Recommendations www.hypertension.ca
28. Canadian Diabetes Association. Clinical Practice Guidelines. April 2013. <http://guidelines.diabetes.ca>
29. Independent Drug Information Service. Preventing Falls in the Elderly: What Primary Care Clinicians can do to Reduce Injury and Death. Alosa Foundation. 2014.
30. Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE. Interventions for preventing falls in older people living in the community. *Cochrane Database of Systematic Reviews* 2012, Issue 9. Art. No.: CD007146. DOI: 10.1002/14651858.CD007146.pub3.
31. Cameron ID, Gillespie LD, Robertson MC, Murray GR, Hill KD, Cumming RG, Kerse N. Interventions for preventing falls in older people in care facilities and hospitals. *Cochrane Database of Systematic Reviews* 2012, Issue 12. Art. No.: CD005465. DOI: 10.1002/14651858.CD005465.pub3.
32. American Geriatrics Society. Geriatrics Evaluation and Management Tools: Falls. Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine. New York, NY: 2013.
33. Uusi-Rasi K, Patil R, Karinkanta S, Kannus P, Tokola K, Lamberg-Allardt C, Sievänen H. Exercise and vitamin D in fall prevention among older women: a randomized clinical trial. *JAMA Intern Med.* 2015 May;175(5):703-11. doi: 10.1001/jamainternmed.2015.0225. PubMed PMID: 25799402.
34. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD; Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *CMAJ.* 2010 Nov 23;182(17):1864-73. doi: 10.1503/cmaj.100771
35. Zarraga IG, Kron J. Oral anticoagulation in elderly adults with atrial fibrillation: integrating new options with old concepts. *J Am Geriatr Soc.* 2013 Jan;61(1):143-50. doi: 10.1111/jgs.12042. Epub 2012 Dec 18. Review.
36. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. *Am J Med.* 2005 Jun;118(6):612-7. PubMed PMID: 15922692.
37. Hutchison, LC, Sleeper, RB. Fundamentals of Geriatric Pharmacotherapy: An Evidence Based Approach. American Society of Health System Pharmacists. Bethesda, Maryland. 2010.
38. PL Detail-Document, Considerations for Anticoagulant Use in Elderly A. Fib Patients. Pharmacist's Letter/Prescriber's Letter. August 2013.

39. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. *J Am Geriatr Soc.* 2012 Apr;60(4):616-31. doi:10.1111/j.1532-5415.2012.03923.x. Epub 2012 Feb 29. Review.
40. Hartikainen S, Lönnroos E, Louhivuori K. Medication as a risk factor for falls: critical systematic review. *J Gerontol A Biol Sci Med Sci.* 2007 Oct;62(10):1172-81. Review. PubMed PMID: 17921433.
41. Sultana J, Spina E, Trifirò G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. *Expert Opin Drug Metab Toxicol.* 2015 Mar 3:1-10. [Epub ahead of print] PubMed PMID: 25736834.
42. Hill KD, Wee R. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. *Drugs Aging.* 2012 Jan 1;29(1):15-30.doi: 10.2165/11598420-000000000-00000. Review.
43. Hill KD, Wee R. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. *Drugs Aging.* 2012 Jan 1;29(1):15-30.doi: 10.2165/11598420-000000000-00000. Review.
44. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. *J Am Geriatr Soc.* 2012 Apr;60(4):616-31. doi:10.1111/j.1532-5415.2012.03923.x. Epub 2012 Feb 29. Review.

MUSCULOSKELETAL & CONNECTIVE TISSUE

Osteoporosis

1. Papaioannou A, Morin S, Cheung A, et al for the Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ November 23, 2010 182:1864-1873; published ahead of print October 12, 2010, doi:10.1503/cmaj.100771, <http://www.cmaj.ca/content/182/17/1864.full.pdf+html>, accessed December 27, 2013.
2. Brown A, Coyle D, Cimon K, Farrah K. Hip Protectors in Long-Term Care: A Clinical and Cost-Effectiveness Review and Primary Economic Evaluation. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008.
3. Hanley David A, Cranney Ann, Jones, Glenville, et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada – summary. CMAJ 2010 0: cmaj.091062
4. Glendenning P, Chew GT, Seymour HM, et al. Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol. Bone. 2009 Nov;45(5):870-5. Doi: 10.1016/j.bone.2009.07.015. Epub 2009 Jul 23.
5. Sanders K, Stuart A, Williamson E, et al. Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women. A Randomized Controlled Trial. JAMA 2010;303(18):1815-22. **Vital D Study**
6. Hanley D, Cranney A, Jones G, et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ 2010;182(12):E610-8. DOI:10.1503/cmaj.080663.
7. Hanley D, Cranney A, Jones G, et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ 2010;182(12):E610-8. DOI:10.1503/cmaj.080663.
8. Hanley D, Cranney A, Jones G, et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ 2010;182(12):E610-8. DOI:10.1503/cmaj.080663.
9. Osteoporosis Canada, The reported potential link between calcium supplement intake and vascular events. Updated January 23, 2013. <http://www.osteoporosis.ca/wp-content/uploads/Calcium-Intake-Statement-Jan-2013.pdf> Accessed January 2, 2014
10. Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010
11. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. In: Avenell A, with The Cochrane Collaboration, eds. Cochrane Database of Systematic Reviews. 2011
12. TheNNT.com. Vitamin D for Preventing Fractures (Elderly, Institutionalized Adults). <http://www.thennt.com/nnt/vitamin-d-for-fracture-prevention-elderly-nursing-home/>, accessed January 2, 2014
13. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341: 10.1136/bmj.c3691
14. Osteoporosis Canada. The reported potential link between calcium supplement intake and vascular events. Information for the patients. Updated January 23, 2013. <http://www.osteoporosis.ca/wp-content/uploads/Calcium-is-Good-Are-Calcium-Supplements-Bad-January-2013.pdf> Accessed January 2, 2014
15. Greenspan SL, Schneider DL, McClung MR, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;136:742-6.
16. Duque G, Close J, de Jager J, et al. Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention. MJA 2010; 193:173-9.
17. Langdahl BL, Rajzbaum, G, Jakob F, et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009;85:484-93.

18. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SM. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. *Lancet*. 2015 Jul 2. pii: S0140-6736(15)61120-5. doi: 10.1016/S0140-6736(15)61120-5. [Epub ahead of print] PubMed PMID: 26144908.
19. Shane E, Burr D, Ebeling PR et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2010;25(11):2267-94.
20. Gomberg SJ, Wustrack RL, Napoli N et al. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. *J Clin Endocrinol Metab* 2011;96(6):1627-32.
21. Hanley DA. Musculoskeletal Disorders: Osteoporosis. E-therapeutics. August 2013, accessed January 3, 2014
22. Ott SM. What is the optimal duration of bisphosphonate therapy? *Cleve Clin J Med*. 2011 Sep;78(9):619-30.
23. Diab DL, Watts NB. Bisphosphonate drug holiday: who, when and how long. *Ther Adv Musculoskelet Dis*. 2013 Jun;5(3):107-11.
24. Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. *JAMA* 2006;296(24):2927-38.
25. Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval and transition to osteoporosis in older women. *N Engl J Med*. 2012;366(3):225-33. Doi: 10.1056/NEJMoa1107142.

Additional References:

- O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. **STOPP**/START criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing*. 2015 Mar;44(2):213-8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16. PubMed PMID: 25324330; PubMed Central PMCID: PMC4339726.
- By the American Geriatrics Society 2015 **Beers** Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2015 Oct 8. doi: 10.1111/jgs.13702. [Epub ahead of print] PubMed PMID: 26446832.
- Hofbauer LC, Rachner TD. More DATA to guide sequential osteoporosis therapy. *Lancet*. 2015 Jul 2. pii: S0140-6736(15)61175-8. doi: 10.1016/S0140-6736(15)61175-8. [Epub ahead of print] PubMed PMID: 26144907.

MUSCULOSKELETAL & CONNECTIVE TISSUE

Pain Management

1. RxFiles *Opioids for Chronic Non-Cancer Pain (CNCP) Management in the Elderly*. RxFiles Q&A. Accessed 01 Aug 2013 at <http://www.rxfiles.ca/rxfiles/uploads/documents/Opioids-Pain-ELDERLY-QandA.pdf>
2. *Canadian Guideline for Safe & Effective Use of Opioids for Chronic Non-Cancer Pain*. Accessed June 2013 at <http://nationalpaincentre.mcmaster.ca/opioid/>
3. Opioid Manager Tool: Point of care tool summarizing Canadian Guidelines:
 - From CEP: http://www.effectivepractice.org/index.cfm?pagePath=CEP_TOOLS/Opioid_Manager&id=23515
 - From NPC: <http://nationalpaincentre.mcmaster.ca/opioidmanager/>
4. *Canadian Guideline for Safe & Effective Use of Opioids for Chronic Non-Cancer Pain*. Accessed June 2013 at <http://nationalpaincentre.mcmaster.ca/opioid/>
5. Opioid Manager Tool: Point of care tool summarizing Canadian Guidelines:
 - From CEP: http://www.effectivepractice.org/index.cfm?pagePath=CEP_TOOLS/Opioid_Manager&id=23515
 - From NPC: <http://nationalpaincentre.mcmaster.ca/opioidmanager/>
6. Ballantyne JC, Mao J. Opioid therapy for chronic pain. *N Engl J Med*. 2003 Nov 13;349(20):1943-53
7. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. *Arch Intern Med*. 2010 Dec 13;170(22):1968-76. See RxFiles Trial Summary online at: <http://www.rxfiles.ca/rxfiles/uploads/documents/Pain-Trial-Summary-Solomon-Elderly-Arthritis.pdf>

Additional References:

O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. **STOPP/START** criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing*. 2015 Mar;44(2):213-8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16. PubMed PMID: 25324330; PubMed Central PMCID: PMC4339726.

By the American Geriatrics Society 2015 **Beers** Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2015 Oct 8. doi: 10.1111/jgs.13702. [Epub ahead of print] PubMed PMID: 26446832.

NEUROLOGY & PSYCHIATRY

Anticholinergics: Reference List of Drugs with Anticholinergic Effects

1. Carnahan RM, Lund BC, Perry PJ, et al. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. *J Clin Pharmacol*. 2006 Dec;46(12):1481-6.
2. National Prescribing Service. Examples of medications with anticholinergic activity. January 2009. Available: <http://www.brisbanesouth.com.au/content/Document/Resources/NPS/NPS%20Anticholinergic%20Medications%20200902.pdf>
3. Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. *Am Geriatr Soc*. 2008 Jul;56(7):1333-41.
4. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. *J R Soc Med*. 2000 Sep;93(9):457-62.
5. Feinberg M. The problems of anticholinergic adverse effects in older patients. *Drugs Aging*. 1993 Jul-Aug;3(4):335-48.
6. Tune LE. Anticholinergic effects of medication in elderly patients. *J Clin Psych*. 2001.
7. Treatment of Dry Mouth. *Canadian Pharmacist's Letter* 2010; 26(10):261006.
8. Drugs with Anticholinergic Activity. *Canadian Pharmacist's Letter* 2011; 27(12):271206.

Additional References

Anticholinergic Cognitive Burden Scale <http://www.indydiscoverynetwork.org/AnticholinergicCognitiveBurdenScale.html>

Campbell NL, Boustani MA, Lane KA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. *Neurology*. 2010 Jul 13;75(2):152-9.

Carrière I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. *Arch Intern Med*. 2009 Jul 27;169(14):1317-24.

Gray SL, Anderson ML, Dublin S, et al. Cumulative use of **strong anticholinergics and incident dementia**: a prospective cohort study [online January 26, 2015]. *JAMA Intern Med*. doi:10.1001/jamainternmed.2014.7663.

Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. *J Am Geriatr Soc*. 2008 Dec;56(12):2203-10. Cumulative anticholinergic exposure across multiple medications over 1 year may negatively affect verbal memory and executive function in older men. Prescription of drugs with anticholinergic effects in older persons deserves continued attention to avoid deleterious adverse effects.

Kalisch Ellett LM, Pratt NL, et al. Multiple anticholinergic medication use and **risk of hospital admission for confusion or dementia**. *J Am Geriatr Soc*. 2014 Oct;62(10):1916-22.

Kennedy J, Deberdt W, Siegal A, et al. **Olanzapine does not enhance cognition** in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. *Int J Geriatr Psychiatry*. 2005 Nov;20(11):1020-7.

Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin 5mg/day in cognitively impaired nursing home residents with urge urinary incontinence. *J Am Geriatr Soc*. 2008 May;56(5):862-70. n=50. 4 weeks. Short-term treatment using oral extended-release oxybutynin 5 mg once daily was safe and well tolerated, with no delirium, in older female nursing home participants with mild to severe dementia. Future research should investigate different dosages and long-term treatment.

McCartney M. Margaret McCartney: **Drugs with anticholinergic side effects** and cognitive decline-cause or effect? *BMJ*. 2015 Mar 16;350:h1428.

- Myint PK, Fox C, Kwok CS, et al. Total **anticholinergic burden and risk of mortality** and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of **EPIC-Norfolk** prospective population study. *Age Ageing*. 2014 Nov 27.
- Paul KJ, Walker RL, Dublin S. Anticholinergic Medications and **Risk of Community-Acquired Pneumonia** in Elderly Adults: A Population-Based Case-Control Study. *J Am Geriatr Soc*. 2015 Mar 2.
- Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. *Arch Intern Med*. 2008 Mar 10;168(5):508-13.
- Sink KM, Thomas J 3rd, Xu H, Craig B, et al. Dual Use of Bladder Anticholinergics and Cholinesterase Inhibitors: Long-Term Functional and Cognitive Outcomes. *J Am Geriatr Soc*. 2008 Apr 1. In higher-functioning NH residents, dual use of ChIs and bladder anticholinergics may result in greater rates of functional decline than use of ChIs alone. The MDS-COGS may not be sensitive enough to detect differences in cognition due to dual use.
- Spence MM, Karim FA, Lee EA, et al. **Risk of Injury in Older Adults Using Gastrointestinal Antispasmodic and Anticholinergic Medications**. *J Am Geriatr Soc*. 2015 Jun;63(6):1197-202.
- Tannenbaum C, Paquette A, Hilmer S, et al. A systematic review of **amnesic and non-amnesic mild cognitive impairment** induced by anticholinergic, antihistamine, GABAergic and opioid drugs. *Drugs Aging*. 2012 Aug 1;29(8):639-58.
- Teramura-Grönblad M, Muurinen S, Soini H, et al. Use of anticholinergic drugs and cholinesterase inhibitors and their association with psychological well-being among frail older adults in residential care facilities. *Ann Pharmacother*. 2011 May;45(5):596-602.
- The American Geriatrics Society **2012 Beers Criteria Update** Expert Panel. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2012 Feb 29.
- Torjesen I. Anticholinergic effects of common drugs are associated with increased **mortality** in over 65s. *BMJ*. 2011 Jun 28;342:d4037.

NEUROLOGY & PSYCHIATRY

Dementia: Behavioural & Psychological Symptoms

1. American Geriatrics Society. Geriatrics Evaluation & Management Tools. New York: American Geriatrics Society; 2013.
2. RxFiles. Management of Behavioural & Psychological Symptoms of DEMENTIA (BPSD). 2011. Available: <http://www.rxfiles.ca/rxfiles/uploads/documents/Psych-BPSD-Newsletter.pdf>
3. http://www.bpac.org.nz/a4e/resources/docs/bpac_A4E_best_practice_guide.pdf
4. British Columbia Ministry of Health. Best Practice Guideline for Accommodating and Managing Behavioural and Psychological Symptoms of Dementia in Residential Care: A Person-Centered Interdisciplinary Approach. 2012. Available: <http://www.health.gov.bc.ca/library/publications/year/2012/bpsd-guideline.pdf>
5. Drouillard ND, Mithani A, Chan PKY. Therapeutic approaches in the management of behavioral and psychological symptoms of dementia in the elderly. BCMJ. 2013 Mar 2013;55(2):90-95.
6. Davidson M, Thorpe L, Bareham J. An introduction to the various types of dementia, their management & treatment. RxFiles. 2014.
7. Shipton EA. Pain assessment in dementia. N Z Med J
8. 2008;121(1286):9–11. http://www.bpac.org.nz/a4e/resources/docs/bpac_A4E_best_practice_guide.pdf
9. Sadowsky CH, Galvin JE. Guidelines for the management of cognitive and behavioral problems in dementia. J Am Board Fam Med. 2012 May-Jun;25(3):350-66.
10. Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015 Mar 2;350:h369. doi: 10.1136/bmj.h369. Review. PubMed PMID: 25731881.
11. American Geriatrics Society. Geriatrics Evaluation & Management Tools. New York: American Geriatrics Society; 2013.
12. American Geriatrics Society. Geriatrics Evaluation & Management Tools. New York: American Geriatrics Society; 2013.
13. http://www.bpac.org.nz/a4e/resources/docs/bpac_A4E_best_practice_guide.pdf
14. American Geriatrics Society. Geriatrics Evaluation & Management Tools. New York: American Geriatrics Society; 2013.
15. American Geriatrics Society. Geriatrics Evaluation & Management Tools. New York: American Geriatrics Society; 2013.
16. Dolder CR, Davis LN, McKinsey J. Use of psychostimulants in patients with dementia. Ann Pharmacother. 2010 Oct;44(10):1624-32.
17. Davidson M, Thorpe L, Bareham J. An introduction to the various types of dementia, their management & treatment. RxFiles. 2014.
18. PL Detail-Document, Pharmacotherapy of Dementia Behaviors. Pharmacist's Letter/Prescriber's Letter. October 2011.
19. PL Detail-Document, Pharmacotherapy of Dementia Behaviors. Pharmacist's Letter/Prescriber's Letter. October 2011.
20. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014 Feb 19;311(7):682-91.
21. Leonard D, Karlamangla A. Dose-Dependent Sedating and Stimulating Effects of Mirtazapine. Proceedings of UCLA Healthcare. 2015 (19).
22. Moore A, Patterson C, Lee L, Vedel I, Bergman H. Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: recommendations for family physicians. Can Fam Physician. 2014 May;60(5):433-8.
23. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191-210.
24. Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease: Review. Cochrane Database of Systematic Reviews 2006; Issue 1.

25. Moore A, Patterson C, Lee L, Vedel I, Bergman H. Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: recommendations for family physicians. *Can Fam Physician*. 2014 May;60(5):433-8.
26. Simon G. ACP Journal Club: new use of atypical antipsychotics was linked to acute kidney injury and all-cause mortality at 90 days. *Ann Intern Med*. 2015 Feb 17;162(4):JC12. doi: 10.7326/ACPJC-2015-162-4-012. PubMed PMID: 25686187.
27. Simon G. ACP Journal Club: new use of atypical antipsychotics was linked to acute kidney injury and all-cause mortality at 90 days. *Ann Intern Med*. 2015 Feb 17;162(4):JC12. doi: 10.7326/ACPJC-2015-162-4-012. PubMed PMID: 25686187.
28. Simon G. ACP Journal Club: new use of atypical antipsychotics was linked to acute kidney injury and all-cause mortality at 90 days. *Ann Intern Med*. 2015 Feb 17;162(4):JC12. doi: 10.7326/ACPJC-2015-162-4-012. PubMed PMID: 25686187.
29. Simon G. ACP Journal Club: new use of atypical antipsychotics was linked to acute kidney injury and all-cause mortality at 90 days. *Ann Intern Med*. 2015 Feb 17;162(4):JC12. doi: 10.7326/ACPJC-2015-162-4-012. PubMed PMID: 25686187.
30. Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. *Am J Alzheimers Dis Other Demen*. 2011 Feb;26(1):10-28.
31. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. *Am J Geriatr Psychiatry*. 2006 Mar;14(3):191-210. PubMed PMID: 16505124.
32. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. *Nat Rev Neurosci*. 2006 Jun;7(6):492-500. Review. PubMed PMID: 16715057.
33. Herrmann N, Lanctôt KL. Do atypical antipsychotics cause stroke? *CNS Drugs*. 2005;19(2):91-103.
34. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. *Am J Geriatr Psychiatry*. 2006 Mar;14(3):191-210.
35. Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggressions and psychosis in Alzheimer's disease (Review). *Cochrane Database Syst Rev*. 2009;4:1-128.
36. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. *JAMA*. 2011 Sep 28;306(12):1359-69.
37. Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. *Am J Alzheimers Dis Other Demen*. 2011 Feb;26(1):10-28.
38. Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. *Am J Alzheimers Dis Other Demen*. 2011 Feb;26(1):10-28.
39. Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. *Am J Alzheimers Dis Other Demen*. 2011 Feb;26(1):10-28.
40. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA; CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *N Engl J Med*. 2006 Oct 12;355(15):1525-38.
41. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, Lawlor BA. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. *Neurology*. 1999 Sep 22;53(5):946-55.
42. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszcak E, Yu LM, Jacoby R; DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. *Lancet Neurol*. 2009 Feb;8(2):151-7.
43. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. *Am J Geriatr Psychiatry*. 2006 Mar;14(3):191-210.
44. The place of antipsychotics in the treatment of the behavioural and psychological symptoms of dementia Available: <http://www.bpac.org.nz/a4e/bpacGuide.asp>

45. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS, Blow FC. Risk of mortality among individual antipsychotics in patients with dementia. *Am J Psychiatry*. 2012 Jan;169(1):71-9.
46. Simon G. ACP Journal Club: new use of atypical antipsychotics was linked to acute kidney injury and all-cause mortality at 90 days. *Ann Intern Med*. 2015 Feb 17;162(4):JC12. doi: 10.7326/ACPJC-2015-162-4-012. PubMed PMID: 25686187.
47. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS, Blow FC. Risk of mortality among individual antipsychotics in patients with dementia. *Am J Psychiatry*. 2012 Jan;169(1):71-9.
48. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. *BMJ*. 2012 Feb 23;344:e977.
49. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS, Blow FC. Risk of mortality among individual antipsychotics in patients with dementia. *Am J Psychiatry*. 2012 Jan;169(1):71-9.
50. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. *BMJ*. 2012 Feb 23;344:e977.
51. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS, Blow FC. Risk of mortality among individual antipsychotics in patients with dementia. *Am J Psychiatry*. 2012 Jan;169(1):71-9.
52. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. *BMJ*. 2012 Feb 23;344:e977.
53. Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. *JAMA Psychiatry*. 2015 May;72(5):438-45. doi: 10.1001/jamapsychiatry.2014.3018. PubMed PMID: 25786075; PubMed Central PMCID: PMC4439579.
54. Jeste DV, Blazer D, Casey D, et al. ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. *Neuropsychopharmacology*. 2008;33:957-970.
55. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. *BMJ*. 2012 Feb 23;344:e977.
56. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. *BMJ*. 2012 Feb 23;344:e977.
57. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. *BMJ*. 2012 Feb 23;344:e977.
58. The place of antipsychotics in the treatment of the behavioural and psychological symptoms of dementia Available: <http://www.bpac.org.nz/a4e/bpacGuide.asp>
59. The place of antipsychotics in the treatment of the behavioural and psychological symptoms of dementia Available: <http://www.bpac.org.nz/a4e/bpacGuide.asp>
60. The place of antipsychotics in the treatment of the behavioural and psychological symptoms of dementia Available: <http://www.bpac.org.nz/a4e/bpacGuide.asp>
61. The place of antipsychotics in the treatment of the behavioural and psychological symptoms of dementia Available: <http://www.bpac.org.nz/a4e/bpacGuide.asp>
62. CATIE-AD - Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *NEJM* 2006; 355:1525-1538.
63. RxFiles Chart ANTIPSYCHOTICS (AP): Frequently Asked Questions Available: <http://www.rxfiles.ca/rxfiles/uploads/documents/members/Cht-Psyc-Neuroleptics.pdf>

64. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *NEJM* 2006; 355:1525-1538. CATIE-AD
65. Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C. Management of behavioral problems in Alzheimer's disease. *Int Psychogeriatr*. 2010;22:346-72.
66. The place of antipsychotics in the treatment of the behavioural and psychological symptoms of dementia Available: <http://www.bpac.org.nz/a4e/bpacGuide.asp>
67. PL Detail-Document, Pharmacotherapy of Dementia Behaviors. Pharmacist's Letter/Prescriber's Letter. October 2011.
68. PL Detail-Document, Pharmacotherapy of Dementia Behaviors. Pharmacist's Letter/Prescriber's Letter. October 2011.
69. Moore A, Patterson C, Lee L, Vedel I, Bergman H. Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: recommendations for family physicians. *Can Fam Physician*. 2014 May;60(5):433-8.
70. Howard RJ, Juszcak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindsay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M; CALM-AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. *N Engl J Med*. 2007 Oct 4;357(14):1382-92.
71. Herrmann N, Gauthier S, et al. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. *Int Psychogeriatr*. 2013 Mar 8:1-9.
72. Wilcock, Gordon K., et al. "Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies." *The Journal of clinical psychiatry* 69.3 (2008): 341-348.

Additional References:

- O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. **STOPP/START** criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing*. 2015 Mar;44(2):213-8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16. PubMed PMID: 25324330; PubMed Central PMCID: PMC4339726.
- By the American Geriatrics Society 2015 **Beers** Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2015 Oct 8. doi: 10.1111/jgs.13702. [Epub ahead of print] PubMed PMID: 26446832.

NEUROLOGY & PSYCHIATRY

Dementia: Cognitive Impairment

1. Davidson M, Thorpe L, Bareham J. An Introduction to the Various Types of Dementia, Their Management & Treatment. April 2014.
2. Kurlowitz, L, & Wallace, M. (Jan 1999). Try This: Best practices in nursing care to older adults: The mini mental state examination (MMSE), Issue #3. Retrieved June 6, 2004, from The John A. Hartford Foundation Institute for Geriatric Nursing, College of Nursing, New York University
3. Durso SC, Sullivan GM, eds. *Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine*. 8th ed. New York: American Geriatrics Society; 2013.
4. Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, Cohen C, Fisk JD, Forbes D, Man-Son-Hing M, Lanctôt K, Morgan D, Thorpe L. Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. *CMAJ*. 2008 Nov 4;179(10):1019-26.
5. Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. *Ann Intern Med* 2008;148:370-8.
6. AAGP position statement: principles of care for patients with dementia resulting from Alzheimer disease.
http://www.aagponline.org/index.php?src=news&submenu=Tools_Resources&srctype=detail&category=Position%20Statement&refno=35.
7. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. *Lancet* 2004; 363: 2105-2115.
8. Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, Cohen C, Fisk JD, Forbes D, Man-Son-Hing M, Lanctôt K, Morgan D, Thorpe L. Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. *CMAJ*. 2008 Nov 4;179(10):1019-26.
9. CCCDTD4
10. Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, Cohen C, Fisk JD, Forbes D, Man-Son-Hing M, Lanctôt K, Morgan D, Thorpe L. Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. *CMAJ*. 2008 Nov 4;179(10):1019-26.
11. A Wentrup et al. Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease. *Drug Des Devel Ther* 2008; 2:245.
12. J Cummings et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs 10 cm²) in Alzheimer's disease. *Dement Geriatr Cogn Disord* 2012; 33:341.
13. Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, Cohen C, Fisk JD, Forbes D, Man-Son-Hing M, Lanctôt K, Morgan D, Thorpe L. Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. *CMAJ*. 2008 Nov 4;179(10):1019-26.
14. Herrmann N, Chau SA, Kircanski I, Lanctot KL. Current and emerging drug treatment options for Alzheimer's disease: a systematic review. *Drugs* 2011;71:2031-65.
15. CCCDTD4
16. PN Tariot et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA* 2004; 291:317.
17. GT Grossberg et al. The safety, tolerability and efficacy of once-daily memantine (28 mg): A multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. *CNS Drugs* 2013; 27:469.
18. AP Porsteinsson et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double blind, placebo-controlled trial. *Curr Alzheimer Res* 2008; 5:83.
19. R Howard et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease (**DOMINO**). *N Engl J Med* 2012; 366:893.
20. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: randomized controlled trial. *JAMA* 2004;291:317-24.
21. Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. *Curr Alzheimer Res* 2008;5:83-9.

22. Peninsula Medical School. Universities of Exeter and Plymouth. Peninsula Technology Assessment Group (PenTAG). The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA111): a systematic review and economic model. June 18, 2010. <http://www.nice.org.uk/nicemedia/live/12248/49789/49789.pdf>.
23. R Howard et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease (**DOMINO**). *N Engl J Med* 2012; 366:893.
24. Peninsula Medical School. Universities of Exeter and Plymouth. Peninsula Technology Assessment Group (PenTAG). The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA111): a systematic review and economic model. June 18, 2010. <http://www.nice.org.uk/nicemedia/live/12248/49789/49789.pdf>.
25. PL Detail-Document, Pharmacotherapy and Advancing Alzheimer's Disease. Pharmacist's Letter/Prescriber's Letter. May 2012.
26. Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, Cohen C, Fisk JD, Forbes D, Man-Son-Hing M, Lanctôt K, Morgan D, Thorpe L. Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. *CMAJ*. 2008 Nov 4;179(10):1019-26.
27. Pharmacotherapy choices for patients with dementia. *Pharmacist's Letter/Prescriber's Letter* 2008;24(5):240510.
28. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand ST, Rochon PA. Syncope and its' consequences in patients with dementia receiving cholinesterase inhibitors: a population based cohort study. *Arch Intern Med*. 2009;169(9):867-73.
29. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand ST, Rochon PA. Syncope and its' consequences in patients with dementia receiving cholinesterase inhibitors: a population based cohort study. *Arch Intern Med*. 2009;169(9):867-73.
30. Hernandez RK, Farwell W, Cantor MD, Lawler EV. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the Veterans Affairs New England Healthcare System. *J Am Geriatr Soc*. 2009;57:1997-2003.
31. Lanctôt KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. *CMAJ* 2003; 169:557.
32. Moore A, Patterson C, Lee L, Vedel I, Bergman H. Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: recommendations for family physicians. *Can Fam Physician*. 2014 May;60(5):433-8.
33. PL Detail-Document, Pharmacotherapy and Advancing Alzheimer's Disease. Pharmacist's Letter/Prescriber's Letter. May 2012.
34. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. *N Engl J Med* 2012;366:893-903.
35. Overshott R, Burns A. Treatment of dementia. *J Neurol Neurosurg Psychiatry* 2005;76(Suppl 5):53-9.
36. Singh S, Dudley C. Discontinuation syndrome following donepezil cessation. *Int J Geriatr Psychiatry* 2003;18:282-4.
37. Kwak YT, Han IW, Suk SH, Koo MS. Two cases of discontinuation syndrome following cessation of memantine. *Geriatr Gerontol Int* 2009;9:203-5.
38. Kwak YT, Han IW, Suk SH, Koo MS. Two cases of discontinuation syndrome following cessation of memantine. *Geriatr Gerontol Int* 2009;9:203-5.
39. Naqvi R, Liberman D, Rosenberg J, Alston J, Straus S. Preventing cognitive decline in healthy older adults. *CMAJ*. 2013 Jul 9;185(10):881-5.
40. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, Yu O, Crane PK, Larson EB. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. *JAMA Intern Med*. 2015 Mar;175(3):401-7. doi: 10.1001/jamainternmed.2014.7663. PubMed PMID: 25621434; PubMed Central PMCID: PMC4358759.
41. Martin BK, Szekely C, Brandt J, et al. Cognitive function over time in the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). *Arch Neurol* 2008;65:896-905.
42. Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. *Br J Psychiatry*. 2013 Sep;203(3):255-64.
43. Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two week physiological DHEA substitution on cognitive performance and well-being in healthy elderly women and men. *J Clin Endocrinol Metab* 1997;82:2363-7.
44. van Niekerk JK, Huppert FA, Herbert J. Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation. *Psychoneuroendocrinology* 2001;26:591-612.
45. Kritz-Silverstein D, von Muhlen D, Laughlin GA, et al. Effects of DHEA supplementation on cognitive function and quality of life. *J Am Geriatr Soc* 2008;56:1292-8.

46. Naqvi R, Liberman D, Rosenberg J, Alston J, Straus S. Preventing cognitive decline in healthy older adults. *CMAJ*. 2013 Jul 9;185(10):881-5.
47. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in Postmenopausal women: the Women's Health Initiative Memory Study: a randomized Controlled trial. *JAMA*. 2003;289:2651-62.
48. Solomon PR, Adams F, Silver A, et al. Ginkgo for memory enhancement. *JAMA* 2002;288:835-40.
49. Dodge HH, Zitzelberger T, Oken BS, et al. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. *Neurology* 2008;70:1809-17.
50. Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S; GuidAge Study Group. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. *Lancet Neurol*. 2012 Oct;11(10):851-9. doi: 10.1016/S1474-4422(12)70206-5. Epub 2012 Sep 6. Review. PubMed PMID: 22959217.
51. Dodge HH, Zitzelberger T, Oken BS, et al. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. *Neurology* 2008;70:1809-17.
52. Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S; GuidAge Study Group. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. *Lancet Neurol*. 2012 Oct;11(10):851-9. doi: 10.1016/S1474-4422(12)70206-5. Epub 2012 Sep 6. Review. PubMed PMID: 22959217.
53. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al; Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for prevention of dementia: a randomized controlled trial. *JAMA*. 2008;300:2253-62.
54. Deijen JB, van der Beek EJ, Orlebeke JF, et al. Vitamin B-6 supplementation in elderly men: effects on mood, memory, performance and mental effort. *Psychopharmacology (Berl)* 1992; 109: 489-96
55. Kang JH, Cook N, Manson J, et al. A randomized trial of vitamin E supplementation and cognitive function in women. *Arch Intern Med* 2006;166:2462-8.
56. Pathansali R, Mangoni AA, Creagh-Brown B, et al. Effects of folic acid supplementation on psychomotor performance and hemorheology in healthy elderly subjects. *Arch Gerontol Geriatr* 2006; 43:127-37.
57. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects. *Neurology* 2008; 71: 430-8.
58. Cassilhas RC, Viana VA, Grassmann V, et al. The impact of resistance exercise on the cognitive function of the elderly. *Med Sci Sports Exerc* 2007;39:1401-7.
59. Willis SL, Tennstedt SL, Marsiske M, et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. *JAMA* 2006;296:2805-14.
60. Smith GE, Housen P, Yaffe K, et al. A cognitive training program based on principles of brain plasticity: results from the improvement in memory with plasticity-based adaptive cognitive training (IMPACT) study. *J Am Geriatr Soc* 2009;57:594-603.
61. Berry AS, Zanto TP, Clapp WC, et al. The influence of perceptual training on working memory in older adults. *PLoS ONE* 2010;5:e11537.
62. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurol*. 2011;10:819-28.
63. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurol*. 2011;10:819-28.
64. Cooper C, Sommerlad A, Lyketsos CG, Livingston G. Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. *Am J Psychiatry*. 2015 Apr;172(4):323-34. doi: 10.1176/appi.ajp.2014.14070878. Epub 2015 Feb 20. Review. PubMed PMID: 25698435.
65. Sublinox Product Monograph. Prepared by: MEDA AB - Solna, Sweden. Date of Preparation: August 16th, 2012.

Additional References:

O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. **STOPP**/START criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing*. 2015 Mar;44(2):213-8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16. PubMed PMID: 25324330; PubMed Central PMCID: PMC4339726.

By the American Geriatrics Society 2015 **Beers** Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2015 Oct 8. doi: 10.1111/jgs.13702. [Epub ahead of print] PubMed PMID: 26446832.

NEUROLOGY & PSYCHIATRY

Depression

1. Taylor, WD. Depression in the Elderly. *N Engl J Med* 2014; 371: 1228-36.
2. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
3. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
4. Frank, Christopher. Pharmacologic treatment of depression in the elderly. *Canadian Family Physician*. 2014; 60: 121-126.
5. Ames, D, Ashby D, Mann AH, et al. Psychiatric illness in elderly residents of Part III homes in one London Borough: prognosis and review. *Age Ageing* 1988; 17 (4): 249-56.
6. Ames, D. Depression among elderly residents of local-authority residential homes. Its nature and the efficacy of intervention. *Br J Psychiatry* 1990; 156: 667-75.
7. Rodda J, Walker Z, Carter J. Depression in older adults. *BMJ* 2011; 343: d5219
8. Rodda J, Walker Z, Carter J. Depression in older adults. *BMJ* 2011; 343: d5219
9. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders: DSM-5 (5th ed.). Arlington, VA: American Psychiatric Publishing.
10. Taylor, WD. Depression in the Elderly. *N Engl J Med* 2014; 371: 1228-36.
11. Practice Guideline for Treatment of Patients with Major Depressive Disorder- Third Edition APA. Available at: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
12. Katz IR, Simpson GM, Curlik SM et al. Pharmacologic treatment of major depression for elderly patients in residential care settings. *J Clin Psychiatry* 1990; 51 (suppl): 41-47.
13. Rodda J, Walker Z, Carter J. Depression in older adults. *BMJ* 2011; 343: d5219.
14. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
15. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
16. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
17. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
18. Kotbi N, Mahgoub N, Odom A. Depression in older adults: How to treat its distinct clinical manifestations. *Current Psychiatry* 2010; 9 (8): 39-45.
19. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
20. Blazer, DG, Hybels CF, Pieper CF. The association of depression and mortality in elderly persons: a case for multiple, independent pathways. *J Gerontol A Biol Sci Med Sci* 2001; 56: M505-9.
21. Charney, DS, Reynolds CF, Lewis L, et al. Depression and bipolar support alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. *Arch Gen Psychiatry* 2003; 60: 664-72.

22. Unutzer, J, Patrick DL, Diehr, P, et al. Quality adjusted life years in older adults with depressive symptoms and chronic medical disorders. *Int Psychogeriatr* 2000; 12: 15-33.
23. Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician. *Dement Geriatr Cogn Discord* 2004; 17 (1-2): 55-64.
24. Mitchell AJ, Subramaniam H. Prognosis of depression in old age compared to middle age: a systemic review of comparative studies... *Am J Psychiatry* 2005; 162: 1588-601.
25. Lict- Strunk E, Van Marwijk HW, Hoekstra T et al. Outcome of depression in later life in primary care: longitudinal cohort study with three years' follow-up *BMJ* 2009; 338; a3079.
26. Rodda J, Walker Z, Carter J. Depression in older adults. *BMJ* 2011; 343: d5219.
27. Rodda J, Walker Z, Carter J. Depression in older adults. *BMJ* 2011; 343: d5219.
28. Manthorpe J, Liffie S. Suicide in later life: public health and practitioner perspectives. *Int J Geriatr Psychiatry* 2010; 25: 1230-8.
29. Practice Guideline for Treatment of Patients with Major Depressive Disorder- Third Edition APA. Available at: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
30. Conwell, Y, Thompson C: Suicidal behavior in elders. *Spcyhiatr Clin North Am* 2008; 31: 333-356.
31. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006
32. Practice Guideline for Treatment of Patients with Major Depressive Disorder- Third Edition APA. Available at: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
33. Rodda J, Walker Z, Carter J. Depression in older adults. *BMJ* 2011; 343: d5219.
34. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
35. Practice Guideline for Treatment of Patients with Major Depressive Disorder- Third Edition APA. Available at: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
36. Manthorpe J, Liffie S. Suicide in later life: public health and practitioner perspectives. *Int J Geriatr Psychiatry* 2010; 25: 1230-8.
37. Rodda J, Walker Z, Carter J. Depression in older adults. *BMJ* 2011; 343: d5219.
38. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
39. Colasanti V, Marianetti M, Micacchi F et al. Tests for the evaluation of depression in the elderly: a systematic review. *Arch Gerontol Geriatr* 2010; 50; 227-30.
40. Rodda J, Walker Z, Carter J. Depression in older adults. *BMJ* 2011; 343: d5219.
41. Kotbi N, Mahgoub N, Odom A. Depression in older adults: How to treat its distinct clinical manifestations. *Current Psychiatry* 2010; 9 (8): 39-45.
42. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006
43. Practice Guideline for Treatment of Patients with Major Depressive Disorder- Third Edition APA. Available at: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
44. Kotbi N, Mahgoub N, Odom A. Depression in older adults: How to treat its distinct clinical manifestations. *Current Psychiatry* 2010; 9 (8): 39-45.
45. Thorpe L. Depression vs. Dementia: How do we assess? *The Canadian Review of Alzheimer's Disease and Other Dementias* 2009 (Sept): 17-21.
46. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)*. Fourth Edition. APA, Washington, DC, 1994.

47. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
48. Thorpe L. Depression vs. Dementia: How do we assess? *The Canadian Review of Alzheimer's Disease and Other Dementias* 2009 (Sept): 17-21.
49. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
50. Rodda J, Walker Z, Carter J. Depression in older adults. *BMJ* 2011; 343: d5219.
51. Lee MJ, Proctor E, Morro-Howell N: Depression outcomes and quality of postdischarge care of elders hospitalized for major depression. *Psychiatr Serv* 2006; 57: 1446-1451.
52. Steffens DC, Pieper CF, Bosworth HB et al. Biological and social predictors of long-term geriatric depression outcome. *Int Psychogeriatr* 2005; 17: 41-56.
53. Cuijpers P, van SA, Smit F, et al. Is psychotherapy for depression equally effective in younger and older patients? A meta-regression analysis. *Int Psychogeriatr* 2009; 21: 16-24.
54. Cuijpers P, van Sam Warmerdam L et al. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. *Depress Anxiety* 2009; 26; 279-88.
55. Gallo JJ, Bogner HR, Morales KH, et al. The effect of a primary care practice-based depression intervention on mortality in older adults: a randomized trial. *Ann Intern Med* 2007; 146: 689-698.
56. Katon Wj, Schoenbaum M, Fan MY. Cost-effectiveness of improving primary care treatment of late-life depression. *Arch Gen Psychiatry* 2005; 62: 11313-1320.
57. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
58. Practice Guideline for Treatment of Patients with Major Depressive Disorder- Third Edition APA. Available at: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
59. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
60. Canadian Agency for Drugs and Technologies in Health. Rapid Response Report: Summary with Critical Appraisal. Antidepressants in Elderly Patients with Major and Minor Depression: A Review of Clinical Effectiveness and Guidelines. Released August 17, 2015.
61. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
62. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
63. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
64. Driscoll HC, Karp JF, Dew MA. Getting better, getting well: understanding and managing partial and non-response to pharmacological treatment of non-psychotic major depression in old age. *Drugs Aging* 2007; 24: 801-814.
65. Dew MA, Whyte EM, Lenze EJ. Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. *Am J Psychiatry* 2007; 164: 892-899.
66. Mandelli L, Serretti A, Zanardi R et al. Antidepressant response in the elderly. *Psychiatry Res* 2007; 152:37-44.
67. Driscoll HC, Basinski J, Mulsant BH et al. Late-onset major depression: clinical and treatment-response variability. *Int J Geriatr Psychiatry* 2005; 20: 661-667.

68. Canadian Agency for Drugs and Technologies in Health. Rapid Response Report: Summary with Critical Appraisal. Antidepressants in Elderly Patients with Major and Minor Depression: A Review of Clinical Effectiveness and Guidelines. Released August 17, 2015.
69. Robinson Rg, Spalletta G. Poststroke depression: a review. *Can J Psychiatry* 2010; 55: 341-9.
70. Green La, Dickinson WP, Nease De et al. AAFP guideline for the detection and management of post-myocardial infarction after depression. *Ann Fam Med* 2009; 7: 71-9.
71. Robinson RG, Jorge RE, Moser DJ et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. *JAMA* 2008; 299:2391-2400.
72. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.
73. Rodda J, Walker Z, Carter J. Depression in older adults. *BMJ* 2011; 343: d5219.
74. Canadian Agency for Drugs and Technologies in Health. Rapid Response Report: Summary with Critical Appraisal. Antidepressants in Elderly Patients with Major and Minor Depression: A Review of Clinical Effectiveness and Guidelines. Released August 17, 2015.
75. Liu BA, Mittmann N, Knowles SR, et al. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. *CMAJ* 1996; 155: 519-527.
76. Movig KL, Leufkens HG, Lenderink SW et al. Association between antidepressant drug and hyponatremia: a case-control study. *Br J Clin Pharmacol* 2002; 53: 363-369.
77. Rodda J, Walker Z, Carter J. Depression in older adults. *BMJ* 2011; 343: d5219.
78. Kennedy SH, Lam RQ, Parikh SV et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. *Journal of Affective Disorders* 2009; 117: S44-S53
79. O'Connor MK, Knapp R, Husain M et al. The influence of age on the response of major depression to electroconvulsive therapy: a CORE report. *Am J Geriatr Psychiatry* 2001; 9: 382-390.
80. Taylor, WD. Depression in the Elderly. *N Engl J Med* 2014; 371: 1228-36.
81. Slotema CW, Blom JD, Hoek HW, et al. Shall we expand the toolbox of psychiatric treatment methods to include repetitive transcranial magnetic stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. *J Clin Psychiatry* 2010; 71: 873-84.
82. Pallanti S, Cantisani A, Grassi G, et al. rTMS age-dependent response in treatment-resistant depressed subjects: a mini-review. *CNS Spectr* 2012; 17; 24-30.
83. Havretsky H, Reinlieb M, St. Cyr N et al. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. *Am J Psychiatry* 2015; 172: 6: 561-569.
84. Frank, Christopher. Pharmacologic treatment of depression in the elderly. *Canadian Family Physician*. 2014; 60: 121-126.
85. Procyshyn RM, Bezchilbnyk-Butler, Jeffries J. *Clinical Handbook of Psychotropic Drugs- 21st Edition (2015)*. Hogrefe Publishing.
86. Procyshyn RM, Bezchilbnyk-Butler, Jeffries J. *Clinical Handbook of Psychotropic Drugs- 21st Edition (2015)*. Hogrefe Publishing.
87. Leonard D, Karlamangla A. Dose-Dependent Sedating and Stimulating Effects of Mirtazapine. *Proceedings of UCLA Healthcare*. 2015 (19).
88. Katona C, Hansen T, Olsen K. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 I elderly patients with major depressive disorder. *International Clinical Psychopharmacology* 2012; 27: 215-223.
89. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health. Toronto, ON: Canadian Coalition for Seniors' Mental Health; 2006.

1. National Institute for Health Care and Excellence. Clinical Knowledge Summaries: Insomnia. Revised 2009. Available: <http://cks.nice.org.uk/insomnia#!scenariorecommendation:1>
2. Bloom HG, Ahmed I, Alessi CA, Ancoli-Israel S, Buysse DJ, Kryger MH, Phillips BA, Thorpy MJ, Vitiello MV, Zee PC. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. *J Am Geriatr Soc.* 2009 May;57(5):761-89. Review. PubMed PMID: 19484833; PubMed Central PMCID: PMC2748127.
3. Bloom HG, Ahmed I, Alessi CA, Ancoli-Israel S, Buysse DJ, Kryger MH, Phillips BA, Thorpy MJ, Vitiello MV, Zee PC. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. *J Am Geriatr Soc.* 2009 May;57(5):761-89. Review. PubMed PMID: 19484833; PubMed Central PMCID: PMC2748127.
4. Bloom HG, Ahmed I, Alessi CA, Ancoli-Israel S, Buysse DJ, Kryger MH, Phillips BA, Thorpy MJ, Vitiello MV, Zee PC. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. *J Am Geriatr Soc.* 2009 May;57(5):761-89. Review. PubMed PMID: 19484833; PubMed Central PMCID: PMC2748127.
5. National Institutes of Health. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. *Sleep.* 2005 Sep;28(9):1049-57. PubMed PMID: 16268373.
6. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. *JAMA.* 1999 Mar 17;281(11):991-9. PubMed PMID: 10086433.
7. Joshi S. Non-pharmacological therapy for insomnia in the elderly. *Clinics Geriatr Med* 2008;24:107– 119.
8. Laine C, Goldman D, Wilson JF. In the clinic: Insomnia. *Ann Int Med* 2008;148(1):ITC13-1– ITC13-16. [PubMed: 18166757]
9. Zee P, Bloom HG. Understanding and resolving insomnia in the elderly. *Geriatrics* 2006;61(5)Special section1-12
10. Joshi S. Non-pharmacological therapy for insomnia in the elderly. *Clinics Geriatr Med* 2008;24:107– 119.
11. Manabe K, Matsui T, Yamaya M, et al. Sleep patterns and mortality among elderly patients in a geriatric hospital. *Gerontology* 2000;46:318–322. [PubMed: 11044786]
12. Fetveit A, Bjorvatn B. Sleep disturbances among nursing home residents. *Internat J Geriatr Psychiatry* 2002;17:604–609.
13. Ersser S, Wiles A, Taylor H, et al. The sleep of older people in hospital and nursing homes. *J Clin Nursing* 1999;8:360–368.
14. National Institute for Health Care and Excellence. Clinical Knowledge Summaries: Insomnia. Revised 2009. Available: <http://cks.nice.org.uk/insomnia#!scenariorecommendation:1>
15. Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. *BMJ.* 2005 Nov 19;331(7526):1169.
16. Buscemi N, Vandermeer B, Friesen C et al. The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: a meta-analysis of RCTs. *JGIM* 2007; 22: 1335-1350.
17. Hardeland R. Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction. *ScientificWorldJournal.* 2012;2012:640389.
18. Spinweber CL. L-tryptophan administered to chronic sleep-onset insomniacs: late-appearing reduction of sleep latency. *Psychopharmacology (Berl).* 1986;90(2):151-5. PubMed PMID: 3097693.
19. Schneider-Helmert D, Spinweber CL. Evaluation of L-tryptophan for treatment of insomnia: a review. *Psychopharmacology (Berl).* 1986;89(1):1-7. PubMed PMID: 3090582.

20. Meolie AL, Rosen C, Kristo D, Kohrman M, Gooneratne N, Aguillard RN, Fayle R, Troell R, Townsend D, Claman D, Hoban T, Mahowald M; Clinical Practice Review Committee; American Academy of Sleep Medicine. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. *J Clin Sleep Med*. 2005 Apr 15;1(2):173-87. Review. PubMed PMID: 17561634.
21. Alberta Health Services. Graval. 2010. Available: <http://www.albertahealthservices.ca/addictionssubstanceabuse/hi-asa-abcs-graval.pdf>
22. Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T. Tolerance to daytime sedative effects of H1 antihistamines. *J Clin Psychopharmacol* 2002;22:511–515.
23. Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. *Am J Alzheimers Dis Other Demen* 2011;26:10-28. Accessed 29 Sep 2011 at <http://aja.sagepub.com/content/26/1/10.abstract?rss=1>
24. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *NEJM* 2006; 355:1525-1538. CATIE-AD
25. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *NEJM* 2006; 355:1525-1538. CATIE-AD
26. Health Canada Advisory. Health Canada advises consumers about important safety information on atypical antipsychotic drugs and dementia June 15, 2005. http://www.hc-sc.gc.ca/ahc-asc/media/advisoriesavis/_2005/2005_63-eng.php
27. FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Available: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/PublicHealthAdvisories/ucm053171.htm>
28. Smith TG. Antipsychotics in dementia - mortality risks and strategies to reduce prescribing. *Evid Based Ment Health*. 2011 Mar 31.
29. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo controlled trials. *JAMA*. 2005;294:1934-43.
30. Sublinox Product Monograph. Prepared by: MEDA AB - Solna, Sweden. Date of Preparation: August 16th, 2012.

Additional References:

- O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. **STOPP**/START criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing*. 2015 Mar;44(2):213-8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16. PubMed PMID: 25324330; PubMed Central PMCID: PMC4339726.
- By the American Geriatrics Society 2015 **Beers** Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2015 Oct 8. doi: 10.1111/jgs.13702. [Epub ahead of print] PubMed PMID: 26446832.

RESPIRATORY

COPD

1. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. *Can Respir J*. 2007 Sep;14 Suppl B:5B-32B.
2. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med*. 2013 Feb 15;187(4):347-65.
3. Criner GJ, Bourbeau J, Diekemper RL, et al. Executive Summary: Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. *Chest*. 2015 Apr 1;147(4):883-93.
4. Global Strategy for Diagnosis, Management, and Prevention of COPD Update 2015 <http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html> accessed March 2015
5. Anthonisen, Nicholas R., et al. "The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial." *Annals of internal medicine* 2005;142(4):233-239.
6. Godtfredsen, N. S., et al. "COPD-related morbidity and mortality after smoking cessation: status of the evidence." *European Respiratory Journal* 2008;32(4):844-853.
7. Fletcher, Charles, and Richard Peto. "The natural history of chronic airflow obstruction." *BMJ* 1977;1(6077):1645-1648.
8. Wongsurakiat, Phunsup, et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. *CHEST Journal* 2004 125(6):2011-2020.
9. Nichol, Kristin L., Leslie Baken, and Andrew Nelson. "Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease." *Annals of internal medicine* 130.5 (1999): 397-403.
10. Mapel DW, Dalal AA, Johnson P, Becker L, Hunter AG. A clinical study of COPD severity assessment by primary care physicians and their patients compared with spirometry. *Am J Med* 2015;128(6):629-637.
11. Criner GJ, Bourbeau J, Diekemper RL, et al. Executive Summary: Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. *Chest*. 2015 Apr 1;147(4):883-93.
12. Vogelmeier, C., Hederer, B et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. *New England Journal of Medicine*, 2011;364(12):1093-1103.
13. Gwynne M, Mounsey A. Would this long-acting bronchodilator be better for your patient? Hickner J, ed. *The Journal of Family Practice*. 2012;61(2):94-96.
14. Rodrigo, Gustavo J., and Hugo Neffen. "Comparison of indacaterol with tiotropium or twice-daily long-acting β -agonists for stable COPD: a systematic review." *CHEST Journal* 2011;142(5):1104-1110.
15. Spiriva product monograph
16. Indacaterol product monograph
17. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2012; 9:CD009157
18. Spiriva product monograph
19. Rodrigo, Gustavo J., Vicente Plaza, and José A. Castro-Rodríguez. "Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review." *Pulmonary pharmacology & therapeutics* 2012;25(1): 40-47.

20. Calverley, P. M., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., ... & Vestbo, J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *New England Journal of Medicine*, 2007;356(8):775-789.
21. Rodrigo, Gustavo J., Vicente Plaza, and José A. Castro-Rodríguez. "Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review." *Pulmonary pharmacology & therapeutics* 2012;25(1): 40-47.
22. Bateman, E. D., M. Van Dyk, and A. Sagriotis. "Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study." *Pulmonary pharmacology & therapeutics* 2008;21(1):20-25.
23. Wedzicha, Jadwiga A., et al. "The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide." *American journal of respiratory and critical care medicine* 2008;177(1):19-26.
24. Coventry, P. A., & Hind, D. Comprehensive pulmonary rehabilitation for anxiety and depression in adults with chronic obstructive pulmonary disease: Systematic review and meta-analysis. *Journal of psychosomatic research*, 2007;63(5):551-565.
25. Criner GJ, Bourbeau J, Diekemper RL, et al. Executive Summary: Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. *Chest*. 2015 Apr 1;147(4):883-93.
26. Puhan, Milo A., et al. "Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease." *Cochrane Database Syst Rev* 2011;10:10.
27. Bourbeau, J., and S. J. Bartlett. Patient adherence in COPD. *Thorax* 2008;63(9): 831-838.
28. Molimard, Mathieu. How to achieve good compliance and adherence with inhalation therapy. *Current Medical Research and Opinion* 2005;21:S33-S37.
29. Molimard, M., Raheison, C., Lignot, S., Depont, F., Abouelfath, A., & Moore, N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. *Journal of aerosol medicine*, 2003;16(3):249-254.
30. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. *Can Respir J*. 2007 Sep;14 Suppl B:5B-32B.
31. SAIL Oxygen Tester's Handbook 2012 edition available at https://sk.lung.ca/testers/study/Tester_Handbook.pdf accessed March 2015
32. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. *Can Respir J*. 2007 Sep;14 Suppl B:5B-32B.
33. Criner GJ, Bourbeau J, Diekemper RL, et al. Executive Summary: Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. *Chest*. 2015 Apr 1;147(4):883-93.
34. McCrory DC, Brown CD. Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2002; :CD003900.
35. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S, Miedinger D, Müller B, Scherr A, Schindler C, Stoeckli R, Viatte S, von Garnier C, Tamm M, Rutishauser J. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. *JAMA*. 2013 Jun 5;309(21):2223-31. doi: 10.1001/jama.2013.5023. PubMed PMID: 23695200.
36. Global Strategy for Diagnosis, Management, and Prevention of COPD Update 2015 <http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html> accessed March 2015
37. Mapel, Douglas W., David Dedrick, and Kourtney Davis. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991–1999. *COPD: Journal of Chronic Obstructive Pulmonary Disease* 2005 2(1):35-41.
38. Celli BR et al. [Predictors of Survival in COPD: More than Just the FEV₁](#). *Respir Med* 2008;102(Suppl 1):S27.
39. Hansen-Flaschen, John. "Chronic obstructive pulmonary disease: the last year of life." *Respiratory care* 49.1 (2004): 90-98.
40. Lankester, Paul N., et al. "An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses." *American journal of respiratory and critical care medicine* 177.8 (2008): 912-927.

41. Emanuel EJ. Palliative and End-of-Life Care. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. eds. *Harrison's Principles of Internal Medicine, 19e*. New York, NY: McGraw-Hill; 2015.
42. Lueppi JD, Schuetz P, Bingisser R, *et al*. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomised clinical trial. *JAMA* 2013;309:2223-31

RESPIRATORY

COPD Inhaler Technique

1. Photograph: Respimat at Inhalation provided by Boehringer Ingelheim. Accessed via: <http://www.respimat.com/services/services/photographs.html> on July 22, 2015. Copyright 2003 Boehringer Ingelheim GmbH, Germany.
2. Ventolin HFA. Product monograph. Copyright 2014 GlaxoSmithKline, Inc.
3. Combivent Respimat. Product monograph. Copyright 2014 Boehringer Ingelheim (Canada) Ltd.
4. Spiriva. Product monograph. Copyright 2012 Boehringer Ingelheim (Canada) Ltd.
5. Onbrez Breezhaler. Product monograph. Copyright 2015 Novartis Pharmaceuticals Canada Inc.
6. Symbicort Turbuhaler. Product monograph. Copyright 2012 AstraZeneca Canada Inc.
7. Advair Diskus. Product monograph. Copyright 2014 GlaxoSmithKline, Inc.
8. Tudorza Genuair. Product monograph. Copyright 2015 AstraZeneca Canada Inc.
9. Breo Ellipta. Product monograph. Copyright 2014 GlaxoSmithKline Inc.
10. Inhalations for Asthma Patients. Retrieved from <http://zaversky.at/thema/inhalation.php> ; accessed August 2015.
11. Advair Diskus. Aidarex Pharmaceuticals LLC. Retrieved from <http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f53cb2d5-3267-401e-9393-dff8357830dd&type=display> ; accessed August 2015.
12. Photograph: Respimat at Inhalation provided by Boehringer Ingelheim. Accessed via: <http://www.respimat.com/services/services/photographs.html> on July 22, 2015. Copyright ©2003 Boehringer Ingelheim GmbH, Germany.
13. Haughney, John, et al. "Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs." Respiratory Medicine CME 3.3 (2010): 125-131.

MISCELLANEOUS

Drug Interactions

1. Types of drug interaction. Available: <http://www.aidsmap.com/Types-of-drug-interaction/page/1730473/>
2. Wooten J. Pharmacotherapy Considerations in Elderly Adults. *Medscape*. South Med J. 2012; 105(8):437-445. Accessed August 30th, 2015.
3. Patel S. Geriatric Pharmacotherapy: A Focus on Medication-Related Emergency Room Admissions in the Elderly. For Emergency Medicine & Complex Continuing Care Services. Orillia Soldiers' Memorial Hospital. February 1, 2015.
4. Shah BM, Hajjar ER. Polypharmacy, adverse drug reactions, and geriatric syndromes. *Clin Geriatr Med*. 2012 May;28(2):173-86.
5. Lindblad CI, Hanlon JT, Gross CR, et al. Clinically important drug-disease interactions and their prevalence in older adults. *Clin Ther*. 2006 Aug;28(8):1133-43.
6. Horn J, Hansten P. Which Drug Interactions Matter in Older Adults?. *Pharmacy Times*. May 2012.
7. Horn J, Hansten P. Get to Know an Enzyme: CYP3A4. *Pharmacy Times*. Sept 2008.
8. Horn J, Hansten P. Drug Transporters: The Final Frontier for Drug Interactions. Dec 2008.
9. PL Detail-Document, Cytochrome P450 Drug Interactions. *Pharmacist's Letter/Prescriber's Letter*. October 2013.

Additional References:

PL Detail-Document, OATP Drug Interactions. *Pharmacist's Letter/Prescriber's Letter*. March 2014.

MISCELLANEOUS

Electrolyte Imbalances

1. Perazella MA, Mahnensmith RL. HYPERkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. *J Gen Intern Med.* 1997 Oct;12(10):646-56. Review. PubMed PMID: 9346463; PubMed Central PMCID: MC1497179.
2. Kugler JP, Husted T. Hyponatremia and HYPERnatremia in the elderly. *Am Fam Physician.* 2000 Jun 15;61(12):3623-30. Review. PubMed PMID: 10892634.
3. Menten J. Oral hydration in older adults: greater awareness is needed in preventing, recognizing, and treating dehydration. *Am J Nurs.* 2006 Jun;106(6):40-9; quiz 50. Review. PubMed PMID: 16728843.
4. Kugler JP, Husted T. Hyponatremia and HYPERnatremia in the elderly. *Am Fam Physician.* 2000 Jun 15;61(12):3623-30. Review. PubMed PMID: 10892634.
5. Kugler JP, Husted T. Hyponatremia and HYPERnatremia in the elderly. *Am Fam Physician.* 2000 Jun 15;61(12):3623-30. Review. PubMed PMID: 10892634.
6. Shah MK, Workeneh B, Taffet GE. HYPERnatremia in the geriatric population. *Clin Interv Aging.* 2014 Nov 19;9:1987-92. doi: 10.2147/CIA.S65214. eCollection 2014. PubMed PMID: 25429210; PubMed Central PMCID: PMC4242070.
7. Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. *J Am Soc Nephrol.* 2007 Oct;18(10):2649-52.
8. Braun MM, Barstow CH, Pyzocha NJ. Diagnosis and management of sodium disorders: hyponatremia and HYPERnatremia. *Am Fam Physician.* 2015 Mar 1;91(5):299-307. PubMed PMID: 25822386.
9. Braun MM, Barstow CH, Pyzocha NJ. Diagnosis and management of sodium disorders: hyponatremia and HYPERnatremia. *Am Fam Physician.* 2015 Mar 1;91(5):299-307. PubMed PMID: 25822386.
10. Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. *Arch Intern Med.* 2000 Sep 11;160(16):2429-36. Review. PubMed PMID: 10979053.
11. Chang WT, Radin B, McCurdy MT. Calcium, magnesium, and phosphate abnormalities in the emergency department. *Emerg Med Clin North Am.* 2014 May;32(2):349-66. doi: 10.1016/j.emc.2013.12.006. Epub 2014 Feb 19. Review. PubMed PMID: 24766937.
12. Arinzon Z, Peisakh A, et. al. Prevalence of hypomagnesemia (HM) in a geriatric long-term care (LTC) setting. *Arch Gerontol Geriatr.* 2010 Jul-Aug;51(1):36-40. doi: 10.1016/j.archger.2009.07.002. Epub 2009 Aug 7. PubMed PMID: 19665241.
13. Saskatoon Health Region Reference Ranges
14. Hypokalemia. Chemocare. Accessed April 2015 at <http://www.chemocare.com/chemotherapy/side-effects/hypokalemia-low-potassium.aspx#.VTVCBCG6eUI>
15. Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. *J Am Soc Nephrol.* 2007 Oct;18(10):2649-52. Epub 2007 Sep 5. Review. PubMed PMID: 17804670.
16. Potassium and Your CKD Diet. National Kidney Foundation. Accessed April 2015 at <https://www.kidney.org/atoz/content/potassium>
17. Pharmacists Letter #240904 – Potassium Content of Foods and Salt Substitutes. September 2008
18. Ingelfinger JR. A new era for the treatment of HYPERkalemia? *N Engl J Med.* 2015 Jan 15;372(3):275-7. doi: 10.1056/NEJMe1414112. Epub 2014 Nov 21. PubMed PMID: 25415806
19. Palmer BF. Managing HYPERkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. *N Engl J Med.* 2004 Aug 5;351(6):585-92. Review. PubMed PMID: 15295051.
20. Zografos GN, Georgiadou D, Thomas D, Kaltsas G, Digalakis M. Drug-induced esophagitis. *Dis Esophagus.* 2009;22(8):633-7. doi: 10.1111/j.1442-2050.2009.00972.x. Epub 2009 Apr 15. Review. PubMed PMID: 19392845.

21. Potassium replacement. CJHP vol. 52, no. 6, December 1999
22. E-CPS Product Monographs 2015
23. Dynamed 2015
24. Pharmacists Letter #240904 – Potassium Content of Foods and Salt Substitutes. September 2008
25. Saskatoon Health Region IV Medication Reference Manual 2015
26. Saskatoon Health Region IV Medication Reference Manual 2015
27. MedSask. Accessed April 2015 at <http://medsask.usask.ca/>
28. Dynamed 2015
29. Liamis G, Milionis H, Elisaf M. A review of drug-induced HYPERnatraemia. *Nephrology Dialysis Transplantation*. 2009 July 16;2:336-346.
30. Dynamed 2015
31. Dietitians of Canada – Food Sources of Sodium. Accessed April 2015 at <http://www.dietitians.ca/Your-Health/Nutrition-A-Z/Minerals/Food-Sources-of-Sodium.aspx>
32. MedSask. Accessed April 2015 at <http://medsask.usask.ca/>
33. MacLeod SM, Cairns JA. Controversial sodium guidelines: Scientific solution or perpetual debate? *CMAJ*. 2015 Feb 3;187(2):95-6.
34. MacLeod SM, Cairns JA. Controversial sodium guidelines: Scientific solution or perpetual debate? *CMAJ*. 2015 Feb 3;187(2):95-6.
35. MacLeod SM, Cairns JA. Controversial sodium guidelines: Scientific solution or perpetual debate? *CMAJ*. 2015 Feb 3;187(2):95-6.
36. Graudal N, Jürgens G, Baslund B, Alderman MH. Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: a meta-analysis. *Am J HYPERTens*. 2014 Sep;27(9):1129-37.
37. Graudal N, Jürgens G, Baslund B, Alderman MH. Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: a meta-analysis. *Am J HYPERTens*. 2014 Sep;27(9):1129-37.
38. Dietitians of Canada – Food Sources of Magnesium. Accessed April 2015 at <http://www.dietitians.ca/Your-Health/Nutrition-A-Z/Minerals/Food-Sources-of-Magnesium.aspx>
39. Chang WT, Radin B, McCurdy MT. Calcium, magnesium, and phosphate abnormalities in the emergency department. *Emerg Med Clin North Am*. 2014 May;32(2):349-66. doi: 10.1016/j.emc.2013.12.006. Epub 2014 Feb 19. Review. PubMed PMID: 24766937.
40. Dynamed 2015
41. Chang WT, Radin B, McCurdy MT. Calcium, magnesium, and phosphate abnormalities in the emergency department. *Emerg Med Clin North Am*. 2014 May;32(2):349-66. doi: 10.1016/j.emc.2013.12.006. Epub 2014 Feb 19. Review. PubMed PMID: 24766937.
42. Pharmacists Letter # 271111 – Treating Magnesium Deficiency. November 2011
43. Chang WT, Radin B, McCurdy MT. Calcium, magnesium, and phosphate abnormalities in the emergency department. *Emerg Med Clin North Am*. 2014 May;32(2):349-66. doi:10.1016/j.emc.2013.12.006. Epub 2014 Feb 19. Review. PubMed PMID: 24766937.
44. Guideline for replacement of magnesium. CJHP vol 52 no 6 December 1999
45. Dynamed 2015
46. Pharmacists Letter # 271111 – Treating Magnesium Deficiency. November 2011
47. Chang WT, Radin B, McCurdy MT. Calcium, magnesium, and phosphate abnormalities in the emergency department. *Emerg Med Clin North Am*. 2014 May;32(2):349-66. doi: 10.1016/j.emc.2013.12.006. Epub 2014 Feb 19. Review. PubMed PMID: 24766937.
48. Dynamed 2015
49. Mentis J. Oral hydration in older adults: greater awareness is needed in preventing, recognizing, and treating dehydration. *Am J Nurs*. 2006 Jun;106(6):40-9; quiz 50. Review. PubMed PMID: 16728843.

50. Shah MK, Workeneh B, Taffet GE. HYPERnatremia in the geriatric population. *Clin Interv Aging*. 2014 Nov 19;9:1987-92. doi: 10.2147/CIA.S65214. eCollection 2014. PubMed PMID: 25429210; PubMed Central PMCID: PMC4242070
51. Braun MM, Barstow CH, Pyzocha NJ. Diagnosis and management of sodium disorders: hyponatremia and HYPERnatremia. *Am Fam Physician*. 2015 Mar 1;91(5):299-307. PubMed PMID: 25822386.
52. Menten J. Oral hydration in older adults: greater awareness is needed in preventing, recognizing, and treating dehydration. *Am J Nurs*. 2006 Jun;106(6):40-9; quiz 50. Review. PubMed PMID: 16728843
53. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. *Am J Kidney Dis*. 2008 Jul;52(1):144-53. doi: 10.1053/j.ajkd.2008.03.004. Epub 2008 May 12. Review. PubMed PMID: 18468754.
54. Menten J. Oral hydration in older adults: greater awareness is needed in preventing, recognizing, and treating dehydration. *Am J Nurs*. 2006 Jun;106(6):40-9; quiz 50. Review. PubMed PMID: 16728843.
55. Perazella MA, Mahnensmith RL. HYPERkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. *J Gen Intern Med*. 1997 Oct;12(10):646-56. Review. PubMed PMID: 9346463; PubMed Central PMCID: PMC1497179.

MISCELLANEOUS

Medication Administration Challenges

1. The Society of Hospital Pharmacists of Australia. Australian Don't Rush to Crush Handbook. Therapeutic Options for people unable to swallow solid oral medications. 1st ed. Collingwood, Vic: The Society of Hospital Pharmacists of Australia, 2011. Print.
2. PL Detail-Document, Meds That Should Not Be Crushed. Pharmacist's Letter/Prescriber's Letter. August 2014.
3. Keele University. Implications of altering oral solid-dose formulations. 2012. Available: <http://www.dysphagia-medicine.com/splitting-and-crushing-tablets.html>
4. Murhammer J, Ross M, Bebout K. Medications that Should Not be Crushed. RxUpdate. 2004 Mar.
5. Hard to swallow: strategies for improving taste of meds. Pharmacist's Letter/Pharmacy Technician's Letter 2010;26(9):260913.
6. Haw C, Stubbs J. Covert administration of medication to older adults: a review of the literature and published studies. J Psychiatr Ment Health Nurs. 2010 Nov;17(9):761-8.
7. Mitchell J. Oral Dosage Forms That Should Not Be Crushed. ISMP. 2014 Jan.

MISCELLANEOUS

Nutritional Supplements & Dietary Considerations for Disease Management

General References:

Canadian Pharmacists Association. Therapeutic Choices for Minor Ailments, 1st Edition. Ottawa, Canada. 2013.

Dynamed. Available at: <http://www.dynamed.com/home/>

eCPS. Available at: <https://www.e-therapeutics.ca/home.whatsnew.action>

Lexicomp. Available at: <http://online.lexi.com/lco/action/home/switch>

Uptodate. Available at: <http://online.lexi.com/lco/action/home/switch>

Calcium:

Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. *BMJ* 2010;341:c3691.

Health Canada Vitamin D and Calcium: Updated Dietary Reference Intakes. Available at: <http://www.hc-sc.gc.ca/fn-an/nutrition/vitamin/vita-d-eng.php>. Accessed July 2015.

Jackson RD, LaCroix AZ, Gass M, et al; Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. *N Engl J Med*. 2006 Feb 16;354(7):669-83.

Manns BJ, Hodsmann A, Zimmerman DL et al. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). *Am J Kidney Dis*. 2010 May;55(5):800-12.

National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis*. 2003 Oct;42(4 Suppl 3):S1-201.

Papaioannou A, Morin S, Cheung AM, et al; Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *CMAJ*. 2010 Nov 23; 182(17):1864-73.

Pharmacist Letter Detail-Document, Calcium and Cardiovascular Risk. *Pharmacist's Letter/Prescriber's Letter*. April 2013.

Co-enzyme Q10:

Banach M, Serban C, Sahebkar A, Ursoniu S, et al; Lipid and Blood Pressure Meta-analysis Collaboration Group. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. *Mayo Clin Proc*. 2015 Jan;90(1):24-34.

Madmani ME, Yusuf Solaiman A, Tamr Agha K, et al. Coenzyme Q10 for heart failure. *Cochrane Database Syst Rev*. 2014 Jun 2;6:CD008684.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. *JAMA Neurol*. 2014 May;71(5):543-52.

Pharmacist Letter Detail-Document, Statin-Associated Muscle Symptoms. *Pharmacist's Letter/Prescriber's Letter*. June 2012.

Iron:

Anemia Review Panel. Anemia Guidelines for Family Medicine. 3rd ed. Toronto: MUMS Guideline Clearinghouse; 2014.

KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. August 2012; 2(4). Available at: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL.pdf. Accessed August 2015.

Magnesium:

Garrison SR, Allan GM, Sekhon RK, et al. Magnesium for skeletal muscle cramps. *Cochrane Database Syst Rev*. 2012 Sep 12;9:CD009402.

Magnesium: CPhA Monograph: Magnesium Salts: Oral eCPS

Pringsheim T, Davenport W, Mackie G, et al; Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis. *Can J Neurol Sci*. 2012 Mar;39(2 Suppl 2):S1-59.

Pharmacist Letter Detail-Document, Comparison of Oral Magnesium Salts. Pharmacist's Letter/Prescriber's Letter. November 2011

Multivitamins-Minerals:

National Institutes of Health. National Cancer Institute. Fact sheet. Antioxidants and cancer prevention. Reviewed January 16, 2014. <http://www.cancer.gov/cancertopics/factsheet/prevention/antioxidants>. (Accessed August 7th, 2015).

Pharmacist Letter *Detail-Document, Eye Vitamins for Age-Related Macular Degeneration*. Pharmacist's Letter/Prescriber's Letter. August 2013.

Pharmacist Letter *Detail-Document, Multivitamins: Who Needs Them?* Pharmacist's Letter/Prescriber's Letter. May 2014.

Zhao LQ, Li LM, Zhu H. The Epidemiological Evidence-Based Eye Disease Study Research Group EY. The effect of multivitamin/mineral supplements on age-related cataracts: a systematic review and meta-analysis. *Nutrients*. 2014 Feb 28;6(3):931-49.

Potassium:

Pharmacist Letter Detail-Document, Comparison of Potassium Salts. Pharmacist's Letter/Prescriber's Letter. September 2014.

Vitamin B1 (Thiamine):

Day E, Bentham PW, Callaghan R, Kuruvilla T, George S. Thiamine for prevention and treatment of Wernicke-Korsakoff Syndrome in people who abuse alcohol. *Cochrane Database of Systematic Reviews* 2013, Issue 7. Art. No.: CD004033.

Latt N, Dore G. Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. *Intern Med J*. 2014 Sep;44(9):911-5.

Pharmacist Letter Detail-Document, Outpatient Alcohol Detox and Relapse Prevention. Pharmacist's Letter/Prescriber's Letter. November 2013.

Vitamin B9 (Folic acid):

Martí-Carvajal AJ, Solà I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. *Cochrane Database of Systematic Reviews* 2015, Issue 1. Art. No.: CD006612.

Vitamin B12 (Cobalamin):

Anemia Review Panel. *Anemia Guidelines for Family Medicine*. 3rd ed. Toronto: MUMS Guideline Clearinghouse; 2014.

Vitamin C:

2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia

Andrés M, Sivera F, Falzon L, et al. Dietary supplements for chronic gout. *Cochrane Database Syst Rev*. 2014 Oct 7;10:CD010156.

Anemia Review Panel. *Anemia Guidelines for Family Medicine*. 3rd ed. Toronto: MUMS Guideline Clearinghouse; 2014.

Choi HK, Gao X, Curhan G. Vitamin C intake and the risk of gout in men: a prospective study. *Arch Intern Med*. 2009 Mar 9;169(5):502-7.

Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. *Cochrane Database Syst Rev*. 2013 Jan 31;1:CD000980.

Huang HY, Appel LJ, Choi MJ, et al ER 3rd. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. *Arthritis Rheum*. 2005 Jun;52(6):1843-7.

Juraschek SP, Miller ER 3rd, Gelber AC. Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. *Arthritis Care Res (Hoboken)*. 2011 Sep;63(9):1295-306.

Ryu KA, Kang HH, Kim SY, et al. Comparison of nutrient intake and diet quality between hyperuricemia subjects and controls in Korea. *Clin Nutr Res*. 2014 Jan;3(1):56-63.

Stamp LK, O'Donnell JL, Frampton C, et al. Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial. *Arthritis Rheum*. 2013 Jun;65(6):1636-42.

Towiwat P, Li ZG. The association of vitamin C, alcohol, coffee, tea, milk and yogurt with uric acid and gout. *Int J Rheum Dis*. 2015 Jun;18(5):495-501.

Vitamin D:

Cameron ID, Gillespie LD, Robertson MC, Murray GR, Hill KD, Cumming RG, Kerse N. Interventions for preventing falls in older people in care facilities and hospitals. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD005465. DOI: 10.1002/14651858.CD005465.pub3.

Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE. Interventions for preventing falls in older people living in the community. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD007146. DOI: 10.1002/14651858.CD007146.pub3.

Health Canada Vitamin D and Calcium: Updated Dietary Reference Intakes. Available at: <http://www.hc-sc.gc.ca/fn-an/nutrition/vitamin/vita-d-eng.php>. Accessed July 2015.

Vitamin E:

Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med.* 2005 Jan 4;142(1):37-46.

Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA.* 2011 Oct 12;306(14):1549-56.

Schürks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. *BMJ.* 2010 Nov 4;341:c5702.

Vitamin K:

Agno W, Gallus AS, Wittkowsky A, et al; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012 Feb;141(2 Suppl):e44S-88S.

Constipation: see Constipation in Older Adults section for references

GERD: see GERD in Older Adults section for references

Heart Failure: see Heart Failure in Older Adults for references

Gout:

Andrés M, Sivera F, Falzon L, et al. Dietary supplements for chronic gout. *Cochrane Database Syst Rev.* 2014 Oct 7;10:CD010156.

Choi HK, Gao X, Curhan G. Vitamin C intake and the risk of gout in men: a prospective study. *Arch Intern Med.* 2009 Mar 9;169(5):502-7.

Huang HY, Appel LJ, Choi MJ, et al ER 3rd. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. *Arthritis Rheum.* 2005 Jun;52(6):1843-7.

Juraschek SP, Miller ER 3rd, Gelber AC. Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. *Arthritis Care Res (Hoboken).* 2011 Sep;63(9):1295-306.

Ryu KA, Kang HH, Kim SY, et al. Comparison of nutrient intake and diet quality between hyperuricemia subjects and controls in Korea. *Clin Nutr Res.* 2014 Jan;3(1):56-63.

Stamp LK, O'Donnell JL, Frampton C, et al. Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial. *Arthritis Rheum.* 2013 Jun;65(6):1636-42.

Towiwat P, Li ZG. The association of vitamin C, alcohol, coffee, tea, milk and yogurt with uric acid and gout. *Int J Rheum Dis.* 2015 Jun;18(5):495-501.

Age-Related Macular Degeneration:

Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. *Arch Ophthalmol.* 2001 Oct;119(10):1417-36.

Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *JAMA*. 2013 May 15;309(19):2005-15.

American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern Guidelines. Age-related macular degeneration. January 2015.

Christen WG, Glynn RJ, Chew EY et al. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study. *Arch Intern Med*. 2009 Feb 23;169(4):335-41.

Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. *Cochrane Database Syst Rev*. 2012 Jun 13;6:CD000253.

Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. *Cochrane Database Syst Rev*. 2012 Nov 14;11:CD000254.

Lawrenson JG, Evans JR. Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration. *Cochrane Database Syst Rev*. 2015 Apr 9;4:CD010015.

Urinary Tract Infections:

Wang CH, Fang CC, Chen NC, et al. *Arch Intern Med*. 2012 Jul 9; 172(13):988-96.

Allan M, Nicolle L. Cranberry juice/tablets for the prevention of urinary tract infection: naturally the best? *Tools for Practice*, March 4, 2013.

TAPERING MEDICATIONS IN OLDER ADULTS

1. Beier MT, Martin CM. Gradual dose reduction and medication tapering: a clinical perspective. *Consult Pharm* 2007;22:628-44.
2. Common oral medications that may need tapering. *Pharmacist's Letter/Prescriber's Letter* 2008;24(12):241208.
3. A practical guide to stopping medications, BPJ; Issue 27; www.bpac.org.nz
4. A practical guide to stopping medications, BPJ; Issue 27; www.bpac.org.nz
5. *Care Beyond Cure: Management of Pain and Other Symptoms*, 4th Edition (2008). Chapter 31: Discontinuation of Drugs in Palliative Care.
6. Gauthier S, Patterson C, Chertkow H, et al. Soucy JP. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). *Can Geriatr J.* 2012 Dec;15(4):120-6.
7. *Care Beyond Cure: Management of Pain and Other Symptoms*, 4th Edition (2008). Chapter 31: Discontinuation of Drugs in Palliative Care.
8. Common oral medications that may need tapering. *Pharmacist's Letter/Prescriber's Letter* 2008;24(12):241208.
9. *Care Beyond Cure: Management of Pain and Other Symptoms*, 4th Edition (2008). Chapter 31: Discontinuation of Drugs in Palliative Care.
10. Virani AS, Bezchlibnyk-Butler KZ, Jeffries JJ, Procyshyn RM, *Clinical Handbook of Psychotropic Drugs*, 19th Rev.Ed. 2012.
11. Tegretol Product Monograph. Prepared by: eCPS. Date of Revision: August 8th, 2013.
12. Neurontin Product Monograph. Prepared by: eCPS. Date of Revision: December 30th, 2013.
13. Gabapentin; Prepared by Lexicomp: Lexi-Drugs.
14. Pregabalin; Prepared by Lexicomp: Lexi-Drugs.
15. Lyrica Product Monograph. Prepared by: eCPS. Date of Revision: January 23rd, 2013.
16. Lamictal Product Monograph. Prepared by: eCPS. Date of Revision: October 22nd, 2013.
17. Lamotrigine; Prepared by Lexicomp: Lexi-Drugs.
18. Keppra Product Monograph. Prepared by: eCPS. Date of Revision: March 5th, 2014.
19. Phenytoin Product Monograph. Prepared by: eCPS. Date of Revision: November 2011.
20. Topamax Product Monograph. Prepared by: eCPS. Date of Revision: August 20th, 2012.
21. Apo-Valproic Capsules Product Monograph. Prepared by: eCPS. Date of Revision: May 11, 2012.
22. Epival Product Monograph. Prepared by: eCPS. Date of Revision: November 8th, 2013.
23. Virani AS, Bezchlibnyk-Butler KZ, Jeffries JJ, Procyshyn RM, *Clinical Handbook of Psychotropic Drugs*, 19th Rev.Ed. 2012.
24. Wellbutrin XL Product Monograph. Prepared by: eCPS. Date of Revision: December 12th, 2012.
25. Bupropion; Prepared by Lexicomp: Lexi-Drugs.
26. Zyban Product Monograph. Prepared by: eCPS. Date of Revision: August 1st, 2013.
27. Mirtazapine; Prepared by Lexicomp: Lexi-Drugs.
28. Remeron Product Monograph. Prepared by: eCPS. Date of Revision: January 15th, 2014.
29. Effexor XR Product Monograph. Prepared by: eCPS. Date of Revision: September 5th, 2012.
30. Venlafaxine; Prepared by Lexicomp: Lexi-Drugs.
31. Pristiq Product Monograph. Prepared by: eCPS. Date of Revision: March 18th, 2013.
32. Desvenlafaxine; Prepared by Lexicomp: Lexi-Drugs.
33. Cymbalta Product Monograph. Prepared by: eCPS. Date of Revision: June 13th, 2013.
34. Duloxetine; Prepared by Lexicomp: Lexi-Drugs.
35. Virani AS, Bezchlibnyk-Butler KZ, Jeffries JJ, Procyshyn RM, *Clinical Handbook of Psychotropic Drugs*, 19th Rev.Ed. 2012.
36. Selective Serotonin Reuptake Inhibitors Product Monograph. Prepared by: eCPS. Date of Revision: March 2014.

37. Paroxetine; Prepared by Lexicomp: Lexi-Drugs.
38. Trazodone Product Monograph. Prepared by: eCPS. Date of Revision: November 2012.
39. Cyclic Antidepressant Product Monograph. Prepared by: eCPS. Date of Revision: November 2012.
40. Common oral medications that may need tapering. Pharmacist's Letter/Prescriber's Letter 2008;24(12):241208.
41. Common oral medications that may need tapering. Pharmacist's Letter/Prescriber's Letter 2008;24(12):241208.
42. Sinemet Product Monograph. Prepared by: eCPS. Date of Revision: February 6th, 2014.
43. Prolopa Product Monograph. Prepared by: eCPS. Date of Revision: June 12th, 2009.
44. Amantadine Product Monograph. Prepared by: eCPS. Date of Revision: October 2009.
45. Amantadine; Prepared by Lexicomp: Lexi-Drugs.
46. Comtan Product Monograph. Prepared by: eCPS. Date of Revision: May 2nd, 2011.
47. Mirapex Product Monograph. Prepared by: eCPS. Date of Revision: November 27, 2012.
48. Pramipexole; Prepared by Lexicomp: Lexi-Drugs.
49. Ropinirole; Prepared by Lexicomp: Lexi-Drugs.
50. Requip Product Monograph. Prepared by: eCPS. Date of Revision: October 11th, 2013.
51. Ropinirole; Prepared by Lexicomp: Lexi-Drugs.
52. Requip Product Monograph. Prepared by: eCPS. Date of Revision: October 11th, 2013.
53. Common oral medications that may need tapering. Pharmacist's Letter/Prescriber's Letter 2008;24(12):241208.
54. Dilsaver SC. Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Saf. 1994 Feb;10(2):103-14.
55. Mathews M, Gratz S, Adetunji B, George V, Mathews M, Basil B. Antipsychotic-induced movement disorders: evaluation and treatment. Psychiatry (Edgmont). 2005 Mar;2(3):36-41.
56. Burns T, Chabannes JP, Demytthenaere K. Switching antipsychotic medications. General recommendations and switching to amisulpride. Curr Med Res Opin. 2002;18:201-208. Available at: <http://www.medscape.com/viewarticle/439736> Accessed March 31, 2006.
57. Quetiapine Product Monograph. Prepared by: eCPS. Date of Revision: December 20th, 2013.
58. Risperidone; Prepared by Lexicomp: Lexi-Drugs.
59. Olanzapine; Prepared by Lexicomp: Lexi-Drugs.
60. Clozaril Product Monograph. Prepared by: eCPS. Date of Revision: May 14th, 2013.
61. Clozapine; Prepared by Lexicomp: Lexi-Drugs.
62. Common oral medications that may need tapering. Pharmacist's Letter/Prescriber's Letter 2008;24(12):241208.
63. Care Beyond Cure: Management of Pain and Other Symptoms, 4th Edition (2008). Chapter 31: Discontinuation of Drugs in Palliative Care.
64. Beta-adrenergic Blocking Agents Product Monograph. Prepared by: eCPS. Date of Revision: February, 2014.
65. Bisprolol, atenolol, metoprolol; Prepared by Lexicomp: Lexi-Drugs.
66. Common oral medications that may need tapering. Pharmacist's Letter/Prescriber's Letter 2008;24(12):241208.
67. Care Beyond Cure: Management of Pain and Other Symptoms, 4th Edition (2008). Chapter 31: Discontinuation of Drugs in Palliative Care.
68. Benzodiazepines Product Monograph. Prepared by: eCPS. Date of Revision: September, 2012.
69. Benzodiazepine toolkit. Pharmacist's Letter/Prescriber's Letter 2011;27(4):270406
70. Common oral medications that may need tapering. Pharmacist's Letter/Prescriber's Letter 2008;24(12):241208.
71. Care Beyond Cure: Management of Pain and Other Symptoms, 4th Edition (2008). Chapter 31: Discontinuation of Drugs in Palliative Care.
72. Common oral medications that may need tapering. Pharmacist's Letter/Prescriber's Letter 2008;24(12):241208.
73. Corticosteroids Product Monograph. Prepared by: eCPS. Date of Revision: October 2011.

74. Care Beyond Cure: Management of Pain and Other Symptoms, 4th Edition (2008). Chapter 31: Discontinuation of Drugs in Palliative Care.
75. Using oral corticosteroids: a toolbox. Pharmacist's Letter/Prescriber's Letter 2010;26(5):260507
76. Nitrates Product Monograph. Prepared by: eCPS. Date of Revision: February, 2010.
77. Nitro-Dur Product Monograph. Prepared by: eCPS. Date of Revision: February 1st, 2011.
78. Nitroglycerin; Prepared by Lexicomp: Lexi-Drugs.
79. Zopiclone Product Monograph. Prepared by: eCPS. Date of Revision: September, 2013.
80. Zolpidem Product Monograph. Prepared by: eCPS. Date of Revision: August 27th, 2013.
81. Opioids Product Monograph. Prepared by: eCPS. Date of Revision: July, 2013.
82. RxFiles. *Opioid Tapering Template*. Available: <http://www.rxfiles.ca/rxfiles/uploads/documents/Opioid-Taper-Template.pdf>
83. Tramacet Product Monograph. Prepared by: eCPS. Date of Revision: March 19th, 2014.
84. Nucynta Product Monograph. Prepared by: eCPS. Date of Revision: May 3rd, 2014.
85. Proton pump inhibitors and rebound acid hypersecretion. Pharmacist's Letter/Prescriber's Letter 2009;25(9):250920.
86. Lioresal Product Monograph. Prepared by: eCPS. Date of Revision: September 18th, 2013.
87. Tizanidine; Prepared by Lexicomp: Lexi-Drugs.